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The aims of the present study were to evalu-
ate the roles of two distinct growth factors
- vascular endothelial growth factor (VEGF)
and hepatocyte growth factor (HGF) - dur-
ing the perinatal period and in acute and
chronic lung injury in preterm infants. In
addition, we measured the effect of early
postnatal dexamethasone on concentrations
of VEGF and HGF in lung lining fluid in
preterm infants.
The patient population comprised se-
lected preterm infants treated in the neo-
natal intensive care unit of the Hospital for
Children and Adolescents of Helsinki Uni-
versity Central Hospital in Helsinki, Fin-
land, between August 1993 and July 1999.
In Study IV, preterm infants were random-
ized to receive either dexamethasone or to
serve as controls. Tracheal aspirate fluid
(TAF) samples were collected from preterm
infants during the early postnatal period by
standardised tracheal lavage. Concentrations
of VEGF and HGF in TAF were analyzed
by commercial VEGF and HGF immunoas-
says, and the results were related to con-
centrations of the secretory component of
immunoglobulin-A. Subjects for immuno-
histochemistry studies were collected be-
tween 1985 and 1999. Immunohistochem-
istry stainings for VEGF and its receptor
Flt-1 were performed on lung samples ob-
tained at autopsy. All studies were per-
formed in the Scientific Laboratory in the
Hospital for Children and Adolescents, and
in the Haartman Institute Laboratory, Uni-
versity of Helsinki.
For VEGF, we found that, in preterm
infants during the early postnatal period,
its postnatal concentrations in TAF in-
creased constantly. Preterm infants had
higher VEGF in TAF than did term infants.
In immunohistochemistry, staining for
VEGF appeared in all fetuses and infants in
bronchial epithelium and alveolar macroph-
ages, and additionally, in fetuses and
preterm infants also in alveolar epithelium.
For Flt-1, we found positive staining in
endothelial cells lining capillaries, veins,
and small arteries, as well as in bronchial
epithelial cells. Preterm infants with more
severe respiratory distress syndrome (RDS),
as well as those subsequently developing
bronchopulmonary dysplasia (BPD), had
lower VEGF in TAF during the early post-
natal period. In BPD infants, additional
staining was discovered for VEGF and Flt-
1 in type-II cells in alveolar epithelium. For
HGF, a negative correlation was evident in
preterm infants between gestational age and
HGF levels in TAF. Preterm infants with
more severe RDS had lower HGF concen-
trations in TAF. Moreover, those infants who
developed BPD had less HGF in TAF than
did those who survived without BPD. We
detected no differences in VEGF levels in
TAF in preterm infants receiving dexam-
ethasone or not. However, infants receiv-
ing dexamethasone had lower HGF levels
in TAF during the early postnatal period.
We therefore conclude that the consis-
tent perinatal pulmonary expression of
VEGF and Flt-1, the higher VEGF in TAF
in the more immature infants, and the post-
natal increase in VEGF in TAF all indicate
a physiological role for VEGF in the devel-
oping human lung. Since infants with more
severe RDS and those subsequently devel-
oping BPD had lower VEGF in TAF, we
suggest that in the preterm infant ,VEGF
plays a role in protection against or in re-
covery from acute lung injury and that
VEGF may have beneficial effects in pre-
venting development of BPD. Lower HGF
in infants with more severe RDS and in
those subsequently developing BPD may
indicate a protective or regenerative role for
HGF. The suppressive effects of glucocorti-
coids on lung development may in part be
mediated by reduction in pulmonary HGF.
Abstract
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In neonatology, premature birth presents a
continuing challenge. Improvements in
treatment, including use of supplemental
oxygen, advances in mechanical ventilation,
surfactant therapy, and antenatal glucocor-
ticoid treatment, have resulted in dramatic
improvement in mortality rates. The more
immature infants - even as small as birth
weight 280 g - have been able to survive
(Muraskas et al 1991). A significant decrease
has occurred in the incidence of BPD in
infants with birth weight over 1500 g.
However, the overall incidence of BPD has
increased, due to the increase in survival of
extremely low birth-weight infants (Parker
et al 1992). At present, the mortality rate
for the most immature premature infants
of less than 1000 g is 35%, and of the sur-
vivors, 30% develop BPD - chronic lung
injury. It is now the most immature infants
that are developing BPD, infants with birth
weights between 500 and 1000 g and who
are born at 24 to 28 weeks of gestation
(Stevenson et al 1998).
In addition to changes in its epidemiol-
ogy, there has also been a change in the
pathophysiology of BPD. Recent findings
in the lungs of very premature infants who
develop fatal BPD include less airway epi-
thelial disease, and only varying degrees of
interstitial fibrosis. Autopsy findings in
infants with fatal BPD include a persistence
of simple terminal air spaces, consistent lack
of significant alveolarization, and
dysmorphic pattern of vascular organization
which together result in emphysematous-
appearing lungs (Chambers et al 1989,
Hislop et al 1990, Van Lierde et al 1991,
Margraf et al 1991, Husain  et al 1998,
Bhatt et al 2001). A newborn of 24 gesta-
tional weeks will have severe pulmonary
prematurity: no alveoli will yet be present,
surfactant production will just be starting,
and the capillary bed will be poorly devel-
oped. Premature birth interrupts normal
alveolar development. Pathogenesis of new
BPD in very immature preterm infants may
therefore result primarily from arrest in
normal lung development; in this develop-
mental disturbance, inhibition of capillary
growth and defects in alveolarization may
also play essential roles (Jobe AH 1999,
Abman 2001).
VEGF and HGF are each known to play
a significant fetal and postnatal develop-
mental role, VEGF in vascular and HGF in
epithelial development. In addition, both
are believed to participate in repair of lung
injury in neonatal animals. Because devel-
opment of BPD may result from develop-
mental arrest, we chose to evaluate the roles
of VEGF and HGF during the perinatal






1. Normal lung development (Fig. 1)
Development of the human lung starts as
the appearance of the tracheal bud in the
developing embryo and ends during early
childhood. Histologically, lung develop-
ment has been divided into five distinct
overlapping stages, based primarily on epi-
thelial processes. The lung vasculature de-
velops parallel to the respiratory tract de-
velopment. In a prematurely born infant,
the early start of respiration may speed func-
tional maturation of the lung; however, the
effect on the lung tissue framework of re-
placement of lung fluid by air has still not
been studied in detail (reviewed in
McDonald 1997, in Bland et al 2000, and
in Haddad et al 2002).
Embryonic stage (1-7 weeks). Organo-
genesis is the early phase of development
during which most organs are laid down.
The trachea and lungs develop as a ventral
outpouching of the foregut at gestation day
26. This ventral outpouch consists of two
parts, the future trachea and two primor-
dial lung buds. At the gestational age of
4.5 weeks, the precedors of five lung lobes
are formed as five tiny saccules. Branching
of the airway tree increases rapidly by di-
chotomous divisions, and by the end of the
7th week the branching has progressed to
subsegmental branches. The pulmonary ar-
teries and the pulmonary vein are estab-
lished at this stage.
Pseudoglandular stage (5-17 weeks).
By the end of this stage, the complete set of
generations of gas-conducting airways of the
future lung are present. Branching of the
airway tree continues, and toward the end
of this stage all the airway divisions down
to the level of alveolar ducts are present
(Kitaoka 1996). The proximal airways are
lined by tall columnar epithelium, the first
ciliated cells appear in the central airways,
and in the peripheral airways the epithe-
lium is lined with undifferentiated cells -
until the alveolar stage. The arterial tree
branches mostly in parallel with the airways,
whereas the veins run in between the the
airway branches in connective tissue septa.
At the end of this stage, the hierarchical
pattern of preacinar airways and blood ves-
sels corresponds to that of the adult lung.
During the process of development of the
lung bud into a fully developed airway tree,
the lung bud undergoes a series of pattern-
ing events termed branching morphogen-
esis. The primary lung bud consists of un-
differentiated epithelial cells surrounded by
mesenchymal cells. Interactions between
mesenchyme and epithelium are required
for airway branching. Of the mediators, fi-
broblast growth factor family members - the
most well-known being fibroblast growth
factor 10 - and their receptors play a criti-
cal role in mediating these epithelial-mes-
enchymal interactions during airway
branching (Bellusci et al 1997).
Canalicular stage (16-26 weeks). The
transition between the pseudoglandular
stage and the canalicular stage is marked
by formation of the prospective gas-ex-
changing tissue, acinus. The early acinus
consists of an airway stem and a spray of
short tubules. The lung parenchyma be-
comes canalized by the multiplication of
capillaries. These capillaries form a loose
three-dimensional network in the mesen-
chyme, and come to lie closer to the epi-
thelial layer, thus forming a peritubular
network. The cuboidal epithelium in the
tubules begins to flatten, type-II epithelial
cells appear as well as type-I epithelial cells
- the principal cells lining the alveoli - and
Review of the literature
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areas of a thin air-blood barrier are formed.
Type-I cells are considered to be derived
from type-II cells during fetal lung devel-
opment. The type-II cells start to accumu-
late lamellar bodies which serve in intrac-
ellular storage of surfactant.
Saccular stage (24 weeks to term). At
this stage, the peripheral airways form ter-
minal clusters of widened air spaces called
saccules. All air spaces distal to the termi-
nal bronchioles lengthen and widen. The
final two or three generations of air spaces
are formed by division of saccules, result-
ing in transitory ducts and the transitory
sac. A massive increase results in the size of
the prospective lung parenchyma. The vol-
ume of intervening interstitial tissue de-
creases, altering the the three-dimensional
structure of the pulmonary capillary bed.
Alveolar stage (from week 28 to 6-24
months postnatally). At birth, the human
lung is in its early phase of alveolarization.
In humans, normal alveolarization may be-
gin as early as 28 gestational weeks and pro-
ceeds rapidly, to achieve 20 to 50% of the
adult number of alveoli at term (Hislop et
al 1986). It is also suggested that alveolar
formation is mainly a postnatal event. The
number of alveoli at birth is not obvious;
estimates vary from 0 to 50 million. More-
over, it is unclear when alveolarization ends;
estimations vary between 6 to 24 months.
Parallel to the alveolar formation the
bilayered capillary network in the paren-
chymal septa transforms into a single-lay-
ered network forming in the end the ma-
ture gas-exchanging unit.
1.1. Alveolar formation
Formation of an alveolus - the architectural
maturation of the lung’s gas-exchange unit
- takes place in the area of transitory ducts
and saccules and consists of two interven-
ing phases. First comes septation: the out-
growth of septa from the walls of the sac-
Stages of human lung development and time-scale (Reviewed in Burri 1997).
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cules that compose the gas-exchange unit
of the architecturally immature lung. Sec-
ondary crest development starts with the
appearance of low ridges along both sides
of the saccular walls, which extend to make
new alveolar septa. These ridges incom-
pletely subdivide the transitory ducts and
saccules into smaller units, the alveoli. The
secondary septa contain a central sheet of
connective tissue, flanked on both sides by
a capillary layer. The secondary septa are
suggested to be formed by the upfolding of
one of the two capillary layers on both sides
of the primary septa. Development of the
secondary cresta involves coordinated out-
growth of epithelial cells, the capillary net-
work, and alveolar myofibroblasts at alveo-
lar septal tips, and the volume fraction of
alveolar type-I cells increases (Massaro et al
1996). Studies in rats have revealed that a
critical period in development occurs in
which septation results. (Massaro et al
1985). The serum concentration of
glucocorticosteroid is low during the time
septation occurs, and increases when septa-
tion ends and remodelling of the alveolar
microvasculature begins (Massaro et al
1996).
The second process is alveolarization:
thinning of the walls of distal air spaces
through flattening of epithelial cells, reduc-
tion in epithelial cell number by apoptosis,
and remodelling of the alveolar wall to form
a single capillary network (Massaro et al
1996). Endothelial cell apoptosis occurs
before capillary formation but not after ves-
sels have formed; inhibition of apoptosis
results in an impaired vascular tissue ar-
rangement (Segura et al 2002). During
alveolarization, all the inner air-space walls
(i.e., primary and secondary septa) contain
a capillary bilayer. In the adult, in contrast,
the interalveolar septum contains only a
single capillary layer occupying the entire
width of the septum. In the primary septa,
the two capillary layers possess interconnec-
tions, whereas in the secondary septa the
capillary network is connected only at the
tip of the septa.  Alveolarization can pro-
ceed only where a capillary layer can be
folded up, which is the case in all septa con-
taining a capillary bilayer.
In developing rats, treatment with
antiangiogenic agents results in decreased
arterial density and alveolarization, suggest-
ing that angiogenesis is necessary for
alveolarization and that injury to the de-
veloping pulmonary circulation may result
in lung hypoplasia (Jakkula et al 2000).
Failure of alveolar formation results in em-
physematous lungs. This is apparent in mice
deficient in factors that participate in al-
veolar formation, e.g., transforming growth
factor-ß and platelet-derived growth factor
A (Kaartinen et al 1995, Bostrom et al
1996, Lindahl et al 1997).
1.2. Lung vascular development
The primary phase of vessel formation oc-
curs during the canalicular stage. Two dif-
ferent processes have been identified in
embryonic pulmonary blood vessel forma-
tion: angiogenesis, the budding and branch-
ing of vessels from pre-existing vessels, and
vasculogenesis, the differentiation of endot-
helial cells from the mesoderm and organi-
zation into a vascular plexus which then
expands and is remodelled into a vascular
tree (Carmeliet et al 1999a, Conway et al
2001). In adults, neovascularization occurs
mainly via angiogenesis, but postnatal
neovascularization has been described as also
occurring by vasculogenesis (Shi et al 1998).
During development, vessels formed by cen-
tral sprouting angiogenesis subsequently
communicate with peripheral vessels that
develop by vasculogenesis (Pardanaud et al
1987, Pardanaud et al 1989, deMello et al
1997). A third additional process is the pro-
cess in which a luminal connection is es-
tablished between these two separate pro-
cesses (deMello et al 2000). The pre-acinar
branches of the pulmonary artery develop
as the airways divide, whereas the intra-aci-
nar or respiratory surface vessels appear as
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the alveoli multiply. Definite bronchial ar-
teries develop between the 9th and 12th
weeks; pre-acinar and resistance arteries are
present by the 28th week. By the 28th week,
a blood-gas barrier has developed of a thick-
ness similar to that in the adult. The devel-
opment and maturation of vascular smooth
muscle tissue lags behind endothelial de-
velopment (Woodcock-Mitchell et al 1993).
Several growth factors - including members
of vascular-endothelial, platelet-derived,
basic- and transforming-growth factor fami-
lies - play a role in pulmonary vascular de-
velopment (Risau W 1997, Petrova et al
1999, Conway et al 2001).
Microvascular maturation. Following
alveolar formation, the capillary network of
the pulmonary parenchyma has to undergo
maturation to assume the adult morphol-
ogy. This structural remodelling represents
the last step in lung development. This pro-
cess involves the transformation of the
bilayered capillary network in the paren-
chymal septa into a single layered network.
The interstitial volume of the parenchymal
septa undergoes a continuous reduction in
mass during all developmental stages de-
spite an increase in total lung volume. The
connective tissue separating the capillary
networks thins out, and the capillaries of
both sides of the septum draw closer to each
other. During this process, the capillary lu-
mina are separated by the cytoplasmic ex-
tension of a single endothelial cell, suggest-
ing that in the end these two capillaries
merge into one. The thinning of the inter-
stitial layer also results in direct cell-to-cell
contact and merging of alveolar epithelial
cells.
In humans, lung volume and the gas-ex-
change area increase about 20- to 25-fold
between birth and adulthood (Zeltner et al
1987a). In the same period, capillary vol-
ume increases by over 35-fold. The capil-
lary  network is not just stretched to fit the
growing gas-exchange surface, but new cap-
illary segments are added within the capil-
lary bed. (Caduff et al 1986). Microvascu-
lar maturation is  thought to end at the age
of 2 to 3 years (Zeltner et al 1987b).
2. Lung injury in the newborn
Before the 19th century, high infant mor-
tality was considered inevitable. In the late
19th century, a closed incubator for prema-
ture infants was introduced, and in 1896
the first special hospital unit was founded
for premature infants. The standard of care
required minimal handling and treatment
of sick premature infants. In the lungs of
newborn infants dying of respiratory dis-
tress, hyaline membranes were first de-
scribed in 1903. Before the use of mechani-
cal ventilation, the natural course of respi-
ratory distress syndrome (RDS) - acute res-
piratory failure - was either death or recov-
ery by 7 days of age. Routine use of oxygen
therapy became the common practise in the
care of premature infants in the 1940’s. In
1953, modern mechanical ventilation of
newborn infants with respiratory failure was
introduced, with the use of a negative-pres-
sure ventilator, and in the 1960’s, treatment
with mechanical ventilation and supple-
mental oxygen became the standard. In the
1960’s, RDS was the leading cause of death
in newborn infants; it was defined as respi-
ratory distress occurring in a newborn in-
fant - mostly in those premature - after the
start of breathing, within the first hours of
life, and as being primarily due to a defi-
ciency in the pulmonary surfactant system
(reviewed in Northway 2000). Respiratory
distress within the first minutes of life may
quickly become life-threatening and require
immediate respiratory and general support-
ive therapy (Verma 1995). Pulmonary
edema and overperfusion resulting from a
patent ductus arteriosus may further worsen
the respiratory failure and aggravate surfac-
tant deficiency.







BPD was first described in 1967 by
Northway et al. They documented the clini-
cal, radiological, and pathological changes
in prematurely born infants with severe
RDS who had been treated with prolonged
mechanical ventilation and high concentra-
tions of inspiratory oxygen. BPD was de-
scribed as an injury and repair process oc-
curring in the immature lung secondary to
high concentrations of supplemental oxy-
gen, pulmonary oxygen toxicity, and pres-
sure-induced trauma (Bonikos et al 1976).
The definition of BPD was revised in 1985;
it was emphasised that such a combination
of oxidant injury and mechanical ventila-
tion resulted in inflammation, fibrosis, and
smooth muscle hypertrophy in the airways
(O'Brodovich et al 1985). The diagnostic
criteria were revised in 1989 as a result of
changes in BPD epidemiology from the re-
quirement of supplemental oxygen at 36
gestational weeks to oxygen at the postna-
tal age of 28 days and a chest radiograph
with findings characteristic of BPD
(Shennan et al 1988). In addition to RDS,
treatment of respiratory failure resulting
from other causes, such as meconium aspi-
ration pneumonia, congestive heart failure,
the Wilson-Mikity syndrome, and congeni-
tal diaphragmatic hernia was recognized to
lead to BPD (reviewed in Northway 2000).
The clinical course of BPD was originally
divided into four stages: Stage I (2 to 3 days)
was a period of acute RDS with respiratory
failure, deposition of hyaline membranes,
atelectasis, and metaplasia and necrosis of
the bronchiolar mucosa. During Stage II (4
to 10 days) the infants were usually weaned
from the respirator, but still needed high
concentrations of oxygen. Histology showed
emphysematous coalescence of alveoli, and
increased bronchiolar necrosis. During Stage
III (10 to 20 days), during the transition to
the chronic stage of BPD, widespread
bronchiolar metaplasia and hyperplasia,
emphysematous alveoli, and atelectasis oc-
curred. In Stage IV (beyond 1 month) his-
tology showed hypertrophy of
peribronchiolar smooth muscle, emphy-
sema, and separation of capillaries from al-
veolar epithelium by thickening of the base-
ment membranes (Northway et al 1967,
Northway 2000).
2.1.1.2. Affecting factors
In several centres the association has been
established between BPD and low birth
weight and gestational age (Avery et al
1987, Kraybill et al 1987, Horbar et al
1988). Moreover, extremely low birth-
weight infants are at increased risk for BPD,
regardless of the severity of RDS (Palta et
al 1991). Mechanical ventilation produces
pulmonary epithelial and endothelial injury,
induces edema formation, and increases
pulmonary inflammation (Dreyfuss et al
1985, Thome et al 1998). Barotrauma to
the immature lung is a causative factor for
development of BPD (Van Marter et al
2000). Free oxygen radicals generated dur-
ing hyperoxic exposure in the lung play a
role in the development of BPD. Immatu-
rity is associated with development of pul-
monary oxygen radicals, and protein oxida-
tion in the neonatal lung is related to de-
velopment of chronic lung disease (Pitkänen
et al 1990, Varsila et al 1995). An inflam-
matory pulmonary reaction following acute
lung injury is an early event in the devel-
opment of BPD (Groneck et al 1995). Sev-
eral proinflammatory mediators in the lung
have been identified as associated with sub-
sequent development of BPD (Merritt et al
1983, Groneck et al 1994). Another post-
natal risk factor for BPD is infection. Ma-
ternal chorionamnionitis accelerates fetal
lung maturation but also causes inflamma-
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tion and subsequent lung injury
(Watterberg et al 1996). Neonatal sepsis,
and pulmonary Ureaplasma urealyticum
colonialization are associated with subse-
quent development of BPD (Rojas et al
1995, Wang et al 1995). Patent ductus
arterious (PDA) is a risk factor for develop-
ment of BPD; moreover, PDA combined
with infection provokes lung injury and
promotes development of BPD (Rojas et al
1995, Gonzalez et al 1996). Obstetric and
maternal risk factors for infant BPD include
fetal asphyxia and poor intrauterine growth
(Hakulinen et al 1988). Other neonatal risk
factors for BPD include low Apgar score and
male sex; RDS is more prevalent and more
severe in male preterm infants (Avery et al
1987, Horbar et al 1988, Kraybill et al
1989, Palta et al 1991, Parker  et al 1992).
2.1.1.3. Development of treatment
The introduction of surfactant therapy has
reduced the severity of RDS and thereby
reduced the effect of oxygen-induced lung
injury. Surfactant treatment also reduces the
severity of BPD (Parker et al 1992, Egberts
et al 1997). Improvements in the manage-
ment of premature infants, including ad-
vances in mechanical ventilation, in use of
supplemental oxygen, and in antenatal glu-
cocorticoid treatment have resulted in a
dramatic reduction in mortality from RDS,
so that it is no longer the leading cause of
death in live-born premature infants. This
effect is seen particularly in extremely low
birth-weight infants (Avery et al 1991,
Stevenson et al 1998, Northway 2000).
Infants surviving with BPD may suffer
persistent pulmonary dysfunction, increased
airway obstruction, airway hyperreactivity,
and hyperinflation, low dynamic compli-
ance, increased functional recidual capac-
ity, and a permanent reduction in alveolar
surface area (Northway et al 1990, Mitchell
et al 1998, Jacob et al 1998). However, it
seems that the milder course of BPD re-
cently has improved long-term outcome as




A significant decrease has occurred in the
incidence of BPD in infants weighing at
birth over 1500 g, although overall inci-
dence of RDS and of BPD has risen. This
can be explained by the fact that survival of
extremely low birth-weight infants (<1000
g) with BPD has increased (Parker et al
1992). Infants as small as birth weight 280
g have survived (Muraskas et al 1991).
Preterm infants born at 24 weeks of gesta-
tion presently survive about half of the time;
of these survivors, half develop BPD. It is
now the most immature infants that develop
BPD; these are infants with birth weights
between 500 and 1000 g and those who are
born at 24 to 28 weeks of gestation
(Stevenson et al 1998).
At present, many of the small preterm
infants who develop BPD have no preced-
ing RDS or just a mild initial respiratory
course. They require mechanical ventilation
with low pressure and oxygen concentra-
tion. The mild RDS in these infants usu-
ally responds favourably to treatment with
surfactant (Charafeddine et al 1999). How-
ever, many of these infants show progres-
sive deterioration in lung function calling
for increasing ventilatory and oxygen re-
quirements. Bacterial or viral infections or
patent ductus arteriosus (PDA) may act as
the triggering agent for deterioration in
pulmonary function (Rojas et al 1995).
2.1.2.2. Pathophysiology
Premature birth interrupts normal alveolar
development. At the age of 24 gestational
weeks, the preterm lung has completely
branched airways, the potential gas ex-
change region is composed of saccular struc-
tures, and septation is just beginning, so
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no alveoli are yet present. The epithelial cells
are just starting to produce surfactant,
which is still not mature. During the canali-
cular stage, capillaries form from mesenchy-
mal progenitors and fuse in the interstitium,
and the interstitium starts to thin (Langston
et al 1984, Coalson et al 1989). The capil-
lary bed is poorly developed and not closely
opposed to epithelium.
Alveolar formation is disturbed by alter-
ations in O2 partial pressure. In rats and in
mice, hyperoxia diminishes septation, re-
sulting in irregularly enlarged alveoli and a
reduced developmental increase in gas-ex-
change surface area. (Shaffer et al 1987,
Massaro et al 1990, Blanco et al 1991,
Blanco et al 1993, Massaro et al 1996,
Warner et al 1998). In addition, lung cap-
illary development is disturbed by
hyperoxia, resulting in decreased arterial
concentration, in medial hyperotrophy in
muscular arteries, and in a diminished num-
ber of alveolar capillaries (Wilson et al 1985,
Randell et al 1990). In rats, hypoxia even
for a short period, impairs septation and
reduces gas exchange surface area, but ac-
celerates thinning of the alveolar wall
(Massaro et al 1989). Both preterm lambs
and preterm baboons undergoing prolonged
mechanical ventilation or ventilation with
100% oxygen show fewer alveoli, enlarged
airspaces, and an arrest of alveolar develop-
ment (Coalson et al 1992, Coalson et al
1995, Albertine et al 1999).
In the 1980’s, Hislop et al had already
noticed that infants who died after mechani-
cal ventilation had fewer alveoli than did
unventilated preterm infants dying of
nonrespiratory causes (Hislop et al 1987).
In contrast to findings in the 70’s and 80’s
in larger surviving infants, recent findings
include less airway epithelial disease, less
severe vascular disease, varying degrees of
interstitial fibrosis, and an abundance of
large, simplified airspaces (Chambers et al
1989, Hislop et al 1990, Van Lierde et al
1991, Margraf et al 1991, Husain et al
1998). Findings in autopsies of very pre-
mature, extremely low birth-weight infants
who develop fatal BPD include persistence
of dilated terminal airspaces, a simplified
distal lung acinus lined with cuboidal epi-
thelium and separated by widened septa,
and a consistent lack of significant
alveolarization resulting in alveolar hypo-
plasia. Abnormal capillary configuration is
also evident; capillaries are positioned
subepithelially, vascular organization shows
a dysmorphic pattern, and capillaries are
extremely sparse in the saccular walls. More-
over, in preterm baboons treated prenatally
with glucocorticoids and postnatally with
surfactant, and subjected to low ventilatory
settings and low inspiratory oxygen, a simi-
lar pattern of lung injury as in human au-
topsy specimens appears: minimal airway
disease, diminished number of capillaries,
and alveolar hypoplasia (Coalson et al 1999).
Use of less oxygen and low peak airway pres-
sures has been shown to result in decreased
severity of interstitial fibrosis. Use of post-
natal antenatal steroid or surfactant therapy
does not, however, alter this arrest of alveo-
lar development (Coalson et al 1997, Husain
et al 1998, Coalson et al 1998).
Arrest of lung development. Patho-
logical findings in the lungs of low birth-
weight infants with BPD include vascular
arrest, alveolar hypoplasia, and adaptive
dysmorphic changes in response to their
premature adaptation to the extrauterine
environment. The use of exogenous surfac-
tant, with less barotrauma and oxygen in-
jury, has resulted in a pattern of injury re-
flecting an extremely immature lung with
impaired alveolar growth and development
owing to developmental arrest, and subse-
quent abnormal reparative processes. Al-
though multiple pathophysiological mecha-
nisms, including inflammation and oxidant
injury, take part in the development of BPD,
the pathogenesis of new BPD encountered
in very immature preterm infants may be
caused primarily by arrest of normal lung
development (Jobe 1999). Capillary devel-
opment plays a role in septation and alveo-
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lar maturation; inhibition of angiogenesis
results in impaired alveolar development,
indicating that angiogenesis is needed for
alveolarization, and injury to the develop-
ing pulmonary circulation may result in
lung hypoplasia (Jakkula et al 2000, Abman
2001).
2.2. Glucocorticoids and the preterm infant
2.2.1. Effects on lung development
In rat pseudoglandular-stage lung explants,
dexamethasone treatment accelerates acqui-
sition of several features of advanced matu-
ration which normally accompany late
stages of fetal development (Oshika et al
1998a). In rats, postnatal dexamethasone
treatment in early life - during the period
of normal septation - accelerates alveolar
wall thinning (Massaro et al 1986). This
treatment, however, inhibits outgrowth of
new interalveolar septa in saccules and di-
minishes the extent of the increase in al-
veolar surface area, resulting in emphyse-
matous-appearing lungs with fewer and
larger airspaces (Massaro et al 1985, Blanco
et al 1989). In addition, in rats, antenatal
dexamethasone treatment suppresses
alveolarization (Okajima et al 2001). The
effect of glucocorticoids on fetal lung matu-
ration is time-dependent as well as dose-
dependent (Bunton et al 1984). Glucocor-
ticoid treatment - like prenatal inflamma-
tion - results in an improvement in postna-
tal lung function but at the same time re-
sults in a decrease in alveolar volume and
number of alveoli (Wíllet et al 2000). In
rats, postnatal glucocorticoid treatment re-
duces interstitial tissue mass and acceler-
ates capillary maturation, resulting in a cap-
illary monolayer instead of a bilayer. In these
same rats, a week after withdrawal of the
treatment, the trend toward precocious
maturation is partially reversed,
interalveolar walls are thickened, and double
capillary networks are again visible; how-
ever, this reversal is only partial, and the
lungs still display their emphysematous
condition (Tschanz et al 1995). These data
suggest that dexamethasone treatment may
interrupt normal alveolar development.
In preterm infants in the early postnatal
period, in addition to effects on alveoli, glu-
cocorticoids reduce in lung parenchymal
cells both cell proliferation and apoptosis
(Luyet et al 2002) and reduce the pulmo-
nary inflammatory response (Groneck et al
1993).
2.2.2. Effects on preterm infant
A clear reduction in neonatal morbidity and
mortality and a decrease in the incidence of
RDS appear when antenatal glucocorticoids
are administered in preterm labour (Crowley
PA 1995). Maternally administered gluco-
corticoids cause fetal growth retardation but
enhance lung compliance, lung volume, and
surfactant production after preterm deliv-
ery (Jobe et al 1998). This beneficial effect
is achieved by a single dose; repeated glu-
cocorticoid courses seem to add nothing to
the effect but rather to cause adverse effects
(French et al 1999). Prenatal steroid therapy
reduces risk for BPD, except in the small-
est infants weighing less than 1000 g
(Papageorgiou et al 1989, Van Marter et al
1990).
Early postnatal dexamethasone treatment
in preterm infants has been shown to re-
duce lung morbidity, mortality, and sever-
ity of RDS, and to shorten the requirement
for mechanical ventilation. Early postnatal
dexamethasone seems to be of beneficial ef-
fect in reducing BPD, although this asso-
ciation is not yet clear. Postnatal dexam-
ethasone, however, has adverse effects on
infant growth and elevates the risk for hy-
pertension, hyperglycaemia, and intestinal
perforation. Moreover, early postnatal dex-
amethasone has adverse effects on long-term
neurodevelopmental outcome (Shinwell et
al 1996, Yeh et al 1997, Bhuta et al 1998,
Garland et al 1999, Sinkin et al 2000, Stark
et al 2001). In extremely low birth-weight
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infants of less than 1000 g, postnatal dex-
amethasone has been found to show no ben-
eficial effect on development of BPD and
to have adverse effects on growth and on
the intestinal perforation rate (Stark et al
2001).
2.3. Persistent pulmonary hypertension of the
newborn
Persistent pulmonary hypertension of the
newborn (PPHN) is a syndrome of acute
respiratory failure characterized by systemic
hypoxemia and elevated pulmonary artery
pressure. PPHN is most common in infants
with underlying diseases such as perinatal
asphyxia, meconium aspiration, RDS, or
lung hypoplasia; it may even be idiopathic
(Morin et al 1995). PPHN is characterized
by vascular intimal thickening related to
increased migration and proliferation of
vascular smooth muscle cells and by elevated
pulmonary artery pressure associated with
vascular intimal thickening of arteries of a
diameter less than 200 µm, arteries which
play an important role in pulmonary blood
pressure and vascular resistance regulation
(Rabinovitch et al 1986, Wagenwoort et al
1989, Morin et al 1995). Lung hypoplasia,
seen as reduced alveolar count and pulmo-
nary artery density, which is induced by
perinatal hypoxia or dexamethasone, may
augment the severity of pulmonary hyper-
tension (le Cras et al 2000, Tang et al 2000).
3. Growth factors and the preterm
lung
3.1. Vascular endothelial growth factor
3.1.1. Background
VEGF family. Members of the vascular en-
dothelial growth factor (VEGF) family play
a crucial role in the growth, differentiation,
and regulation of vascular and lymphatic
endothelial cells (reviewed in Carmeliet et
al 1999a). The first member of the family,
VEGF-A (referred to as VEGF, here) was
discovered in 1983 (Senger et al 1983). It
was found to be a potent endothelial cell-
specific mitogen capable of regulating
physiological and pathological angiogenesis
and in 1989 termed as VEGF (Ferrara et al
1989, Plouet et al 1989, Leung et al 1989).
A novel protein sharing marked similarity
with VEGF was isolated in 1991 and
termed placental growth factor PlGF
(Maglione et al 1991). More members of
the family, including VEGF-B (Olofsson et
al 1996) and VEGF-C (Joukov et al 1996)
were discovered in 1996. VEGF-C was iden-
tified as acting, in addition to its role in
angiogenesis, as a regulator of
lymphangiogenesis during development
and in pathological conditions (Kukk et al
1996, Jeltsch et al 1997, Cao et al 1998,
Eichmann et al 1998). VEGF-D was iden-
tified in 1998 (Achen et al 1998). Addi-
tional Orf-virus encoded members of the
family were discovered in parapox virus in
1998 and termed VEGF-Es (Ogawa et al
1998, Meyer et al 1999).
VEGF-A isoforms. The human VEGF
gene is located on chromosome 6p21.3
(Vincenti et al 1996). Alternative exon
splicing of a single VEGF gene results in at
least six different isoforms: VEGF121,
VEGF145, VEGF165, VEGF183,
VEGF189, and VEGF206 (Houck et al
1991, Tisher et al 1991, Shima et al 1996,
Poltorak et al 1997, Jingjing et al 1999).
VEGF165 is the predominant molecular
species produced by the cells (Houck et al
1991). Whereas VEGF165 is basic, and is
a heparin-binding protein, VEGF121 is
weakly acidic and does not bind to heparin.
VEGF189 and VEGF206 are more basic
and bind to heparin with even greater af-
finity than does VEGF165 (Houck et al
1992). VEGF121 is a freely diffusible pro-
tein; VEGF165 is also secreted, although a
significant fraction remains bound to the
cell surface and the extracellular matrix. In
contrast, although VEGF189 and
VEGF206 are almost completely seques-
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tered in the extracellular matrix, these
isoforms may be released in a soluble form
(Park et al 1993, Keyt et al 1996a). VEGF
proteins may become available to endothe-
lial cells by at least two different mecha-
nisms: as freely diffusible proteins
(VEGF121, VEGF165) or following pro-
tease activation and cleavage of the isoforms
(VEGF189 and VEGF206). Loss of the he-
parin binding of VEGF results in reduction
of mitogenic activity of vascular endothe-
lial cells (Keyt et al 1996a).
VEGF receptors. VEGF-A has two re-
ceptors that bind to it with high affinity:
Flt-1 (fms-like tyrosine kinase, VEGFR1)
and Flk-1 (fetal liver kinase-1, VEGFR2).
Both receptors have an extracellular domain,
a single transmembrane region, and a ty-
rosine kinase domain. Flt-1 has higher af-
finity for recombinant human VEGF165
than does Flk-1 (de Vries et al 1992, Terman
et al 1992, Veikkola et al 2000). An alter-
natively spliced soluble form of Flt-1 (sFlt-
1) has also been identified that binds VEGF
(Kendall et al 1993). VEGF mutants that
bind selectively to Flk-1 are able to induce,
in vivo, mitogenesis and chemotaxis in en-
dothelial cells, and induce angiogenesis and
permeability, whereas Flt-1 selective mu-
tants cannot perform such abilities (Keyt
et al 1996b, Gille et al 2001). Flk-1 activa-
tion has been shown to be required for the
antiapoptotic effects of VEGF in endothe-
lial cells, as well as for formation of capil-
lary-like structures (Gerber et al 1998a,
Koolwijk et al 2001). A third tyrosine ki-
nase receptor that binds VEGF-C and
VEGF-D was identified as Flt-4 (VEGFR3);
in contrast to Flt-1 and Flk-1, expression
of Flt-4 is largely restricted to lymphatic
and venous endothelium during fetal de-
velopment and to lymphatic endothelium
in adults (Aprelikova et al 1992, Pajusola
et als 1992, Shibuya et al 1995, Kaipainen
et al 1995). There exists an additional
isoform-specific receptor that binds
VEGF165 but not VEGF121. This recep-
tor is identical to human neuropilin-1,
which is involved in regulation of neuronal
cell guidance by semaphorins (Soker et al
1998)
Regulation of VEGF. Oxygen tension
is a key regulator of VEGF gene expression
(Shweiki et al 1992); VEGF is rapidly and
reversibly induced by exposure to low pO2,
and hypoxia induces both Flt-1 and Flk-1
expression in vitro (Minchenko et al 1994,
Shima et al 1995, Brogi et al 1996,
Waltenberger  et al 1996). In acute hypoxia,
VEGF mRNA in rat lungs increases within
hours, whereas chronic hypoxia causes in-
creased expression of Flt-1 and Flk-1 (Tuder
et al 1995). Similarities exist between the
mechanisms leading to hypoxic regulation
of VEGF and of erythropoietin (Goldberg
et al 1994). A hypoxia-specific enhancer is
required for the hypoxia-inducibility of
VEGF, and hypoxia-inducible factors (HIF)-
1 and -2, essential mediators of O2 homeo-
stasis, have been identified as these factors
(Liu et al 1995). VEGF upregulation in re-
sponse to hypoxia is also augmented
postranscriptionally by increased  mRNA
stability (Ikeda et al 1995). A number of
cytokines, hormones, and growth factors are
able to upregulate VEGF mRNA expres-
sion in various cell types. A role in inflam-
mation is suggested by upregulation of
VEGF expression by inflammatory media-
tors (Ben-Av et al 1995, Nauck et al 1997,
Horiuchi et al 1997). Epidermal growth
factor, transforming growth factor-ß,
keratinocyte growth factor, and platelet-
derived growth factor have been shown to
induce VEGF mRNA expression
(Pertovaara et al 1994, Brogi et al 1994,
Frank et al 1995). VEGF can upregulate its
receptors Flt-1, Flk-1, and sFlt-1 (Barleon
et al 1997, Kremer et al 1997, Shen et al
1998).
Biological activities of VEGF. VEGF
is a mitogen for vascular endothelial cells
derived from arteries, veins, and lymphat-
ics, but it lacks significant mitogenic ac-
tivity for other cell types (Ferrara  2001).
VEGF is suggested to act as a paracrine fac-
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tor, secreted by nonendothelial cells and
modulating activities in adjacent vascular
endothelium (Shifren et al 1994, Brogi et
al 1996). VEGF is a major regulator of nor-
mal and pathological angiogenesis, endot-
helial cell differentiation, and maintenance
of existing vessels, and is a survival factor
for endothelial cells (Leung et al 1989, Pep-
per et al 1991, Shifren et al 1994, Alon et
al 1995, Gerber et al 1998a). In addition to
prosurvival activity, VEGF induces expres-
sion of antiapoptotic proteins in endothe-
lial cells (Gerber et al 1998b). It induces
expression of the serine proteases urokinase-
type and tissue-type plasminogen activators,
as well as metalloproteinase interstitial col-
lagenase in endothelial cells (Pepper et al
1991, Unemori et al 1992). VEGF is known
also as a vascular permeability factor based
on its ability to induce fenestration in en-
dothelial cells and vascular leakage (Dvorak
et al 1995, Roberts et al 1995).
In addition to effects on vascular endot-
helium, VEGF action may be involved in
the survival or proliferation of alveolar epi-
thelial cells. VEGF induces human fetal air-
way epithelial-cell proliferation in vitro, and
treatment of rats with the VEGF-receptor
blocker SU5416 enhances apoptosis in al-
veolar septal cells and leads to enlargement
of air spaces (Kasahara et al 2000, Brown et
al 2001).
Effect of corticosteroids on VEGF.
Corticosteroids reduce VEGF expression
and attenuate VEGF expression induced by
inflammatory mediators or by hypoxia in
vitro (Nauck et al 1997, Horiuchi et al
1997, Klekamp et al 1997, Nauck et al
1998). In contrast, in vivo, dexamethasone
may raise pulmonary VEGF concentrations
in preterm infants receiving postnatal dex-
amethasone (D'Angio et al 1999, Bhatt et
al 2000).
3.1.2. VEGF and lung development
Prenatal expression of VEGF. VEGF is
expressed at high levels in the lungs of nor-
mal human adults undergoing physiological
endothelial turnover (Berse et al 1992). In
human fetuses, mRNA for VEGF can be
detected in all tissues, most abundantly in
lung, kidney, and spleen. VEGF is, in fe-
tuses and similarly in adults, localized in
epithelial cells and myocytes, including the
smooth muscle cells lining blood vessels
(Shifren et al 1994, Acarregui et al 1999).
Inactivation even of a single VEGF allele
in mice results in early embryonic lethal-
ity. VEGF-/+ embryos are growth retarded
and exhibit a number of developmental
anomalies; formation of blood vessels is ab-
normal in heterozygous VEGF-deficient
embryos and is even more impaired in ho-
mozygous VEGF-deficient embryos
(Carmeliet et al 1996, Ferrara et al 1996).
Part of this developmental block can be re-
versed by addition of exogenous VEGF
(Bautch et al 2000). In an isoform-specific
knockout of the VEGF gene, all of the
VEGF120/120 mice die within 2 weeks af-
ter delivery (Carmeliet et al 1999b). In ad-
dition, the isoform-specific knockouts
VEGF164-/- and VEGF188-/- display vas-
cular defects in several tissues including in
the pulmonary vasculature (Ng et al 2001),
indicating that the functions of heparin-
binding isoforms of VEGF cannot be re-
placed by VEGF120.
Prenatal expression of VEGF recep-
tors. In mice, Flt-1 is expressed in both
embryos and adults, in endothelium dur-
ing vascular development (Peters et al
1993). In contrast, Flk-1 is expressed in
vascular endothelium in mouse fetuses, but
its expression is reduced in the adults
(Terman et al 1992, Millauer et al 1993).
Gene-targeting studies have demonstrated
that in mice, both Flt-1 and Flk-1 are es-
sential for the development of the embry-
onic vasculature. Mouse embryos homozy-
gous for a targeted mutation in the Flt-1 or
Flk-1 locus die in utero. In Flt-1-/- mice,
endothelial cells develop but fail to orga-
nize in the normal vascular channels,
whereas Flk-1-/- mice lack vasculogenesis,
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Lung injury. In animal studies, after pro-
longed exposure to hyperoxia, levels of
VEGF mRNA and protein decrease, as does
Flt-1 and Flk-1 expression, a phenomenon
that has been suggested to contribute to the
pathophysiology of oxygen-induced lung
injury and to impaired vascular repair in
such injury (Johnston et al 1996, Klekamp
et al 1999). In newborn rabbits during
hyperoxic lung injury, pulmonary expres-
sion of VEGF mRNA and protein are de-
creased, whereas during the recovery period
in relative hypoxia, the expression of VEGF
increases specifically in alveolar type-II cells
(Maniscalco et al 1995, Maniscalco et al
1997). In mice overexpressing IL-13, sur-
vival after exposure to 100% oxygen is pro-
longed. In these mice, VEGF levels are in-
creased in bronchoalveolar lavage, and this
increase is even higher in those exposed to
hyperoxia. That antibody neutralization of
VEGF reduces survival of these mice indi-
cates that production of VEGF protects
against hyperoxic lung injury (Corne et al
2000).
BPD. In a premature-baboon model of
BPD, capillary density does not increase,
and capillaries are dysmorphic and not sub-
epithelial; moreover VEGF and Flt-1 ex-
pression are significantly decreased
(Maniscalco et al 2002). The lung specimens
obtained by autopsy in infants dying of BPD
show an abnormal distribution of alveolar
capillaries and thickened alveolar septa in
addition to decreased expression of VEGF
fail to develop blood islands, present dis-
rupted hematopoietic precursors, and fail
to develop organized blood vessels (Fong et
al 1995, Shalaby et al 1995). However, that
mice lacking the tyrosine kinase domain of
Flt-1 but still having the ligand-binding
region develop normal vessels indicates that
Flt-1 has, during development, primarly a
non-signaling function (Hiratsuka et al
1998). PlGF potentiates the angiogenetic
response to VEGF via binding to Flt-1; in
mice deficient in PlGF, a factor binding to
Flt-1 but not to Flk-1, embryonic angio-
genesis is unaffected (Carmeliet et al 2001).
Angiogenesis, plasma extravasation, and
collateral growth in these mice is, however,
impaired during ischemia, inflammation,
wound-healing, and cancer, indicating a role
for Flt-1 in the angiogenetic response to
pathological conditions (Carmeliet et al
2001). Inhibition of Flk-1 with receptor
blocker in rats induces alveolar septal cell
apoptosis and leads to emphysematous en-
largement of airspaces, indicating that Flk-
1 signalling is required for maintenance of
alveolar structures (Kasahara et al 2000).
Flt-4 expression is restricted to lymphatic
endothelium during development
(Kaipainen et al 1995). Flt-4 plays a cru-
cial role in lymphatic development, as
shown by inhibition of lymphangiogenesis
in transgenic mice expressing soluble Flt-4
(Mäkinen et al 2001). That mice deficient
in Flt-4 show cardiovascular failure suggests
that Flt-4 plays an essential role in embry-
onic cardiovascular development before the
emergence of lymphatic vessels (Dumont et
al 1998).
VEGF and postnatal lung develop-
ment. In preterm infants, VEGF levels in
serum increase rapidly postnatally
(Malamitsi-Puchner et al 1999). Early post-
natal inactivation of VEGF in mice either
by administration of sFlt-1 or by inducible
gene targeting results in increased mortal-
ity, stunted body growth, and impaired or-
gan development - and when the inhibi-
tion is more severe - in nearly complete
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growth arrest and lethality. Interestingly,
after the fourth postnatal week, dependence
on VEGF is eventually lost (Gerber et al
1999). Treatment of mice postnatally by an
inhibitor of  Flk-1 results in decreased
alveolarization and arterial density, suggest-
ing that the VEGF-Flk-1 system is required
for normal postnatal alveolar development
(Jakkula et al 2000).
3.1.3. VEGF and injury in the preterm
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and Flt-1 (Bhatt et al 2001). These data
suggest that development of BPD is associ-
ated with impaired lung microvasculature
and that a possible mechanism is disrup-
tion of VEGF and Flt-1 expression. Loss of
the hypoxia-inducible transcription factor-
2-a (HIF-2-a), a promoter for VEGF, causes
fatal RDS in neonatal mice due to insuffi-
cient surfactant production by alveolar type-
II cells. VEGF levels in alveolar cells are
decreased in these HIF-2-a-deficient fetuses;
mice with a deficiency in the longer
isoforms of VEGF or in the HIF-binding
site in the VEGF promotor die of RDS.
Capillary development in septa is impaired
prior to birth: capillaries fail to remodel
properly and are separated from the lumen.
Intrauterine inhibition of Flk-1 results as
well in defects in alveolarization and also
in lung prematurity. Intrauterine or post-
natal intratracheal instillation of VEGF
stimulates conversion of glycogen to sur-
factant, improves lung function, and pro-
tects mice against RDS (Compernolle et al
2002). These data suggest a protective or
reparative role for VEGF in neonatal lung
injury in addition to its role in lung devel-
opment.
Pulmonary hypertension. Flk-1 inhi-
bition combined with prolonged hypoxia
in rats results in severe pulmonary hyper-
tension (Taraseviciene-Stewart et al 2001).
Interestingly, VEGF expression is higher in
lungs of newborn infants suffering from
pulmonary hypertension. Shehata et al sug-
gest this to be a reflection of an unsuccess-
ful attempt to increase the pulmonary vas-
cular bed in hypoplastic lungs to alleviate
the associated pulmonary hypertension
(Shehata et al 1999).
3.2. Hepatocyte growth factor
3.2.1. Background
Hepatocyte growth factor (HGF), also called
scatter factor or lung fibroblast-derived
mitogen, is a heterodimeric (69-kD a-chain
and 34-kB ß-chain) heparin-binding
growth factor with structural homology to
plasminogen (Nakamura et al 1984,
Nakamura et al 1989, Weidner et al 1991).
HGF is synthesized in a variety of cell types,
including fibroblasts, macrophages, smooth
muscle cells, and epithelial cells (Mason
2002). It acts as a mesenchymal- or stroma-
derived growth factor which stimulates cell
growth, cell motility, and morphogenesis
in epithelial cells in a wide range of organs
(Stoker et al 1989, Gherardi et al 1989,
Montesano et al 1991). In the lungs, HGF
acts as a mitogen and motogen for alveolar
type-II and bronchiolar cells and is sug-
gested to be responsible for most of the
stimulatory activity of type II cells in the
lavage fluid (Panos et al 1993, Shiratori et
al 1995, Mason et al 1996). HGF induces
epithelial cell proliferation and formation
of structures resembling alveolar and bron-
chial tissues in fetal rat and mice lung cul-
tures (Itakura et al 1997, Sato et al 1997).
In the developing lung, HGF and c-MET/
HGF mRNA are expressed in mesenchyme
and in epithelium, respectively. In fetal lung
cultures, added HGF stimulates branching
morphogenesis; moreover, HGF neutraliza-
tion assays or translation arrest result in
inhibition of epithelial branching (Ohmichi
et al 1998). These data suggest a role for
HGF in the morphogenesis both of alveo-
lar and of bronchial epithelia during devel-
opment. In addition, HGF stimulates
growth and migration of endothelial cells
(Bussolino et al 1992). Several growth fac-
tors induce HGF mRNA expression or
HGF secretion, including epidermal growth
factor, platelet-derived growth factor, basic
fibroblast growth factor, acidic fibroblast
growth factor, and transforming growth fac-
tor-a (Gohda et al 1994).
HGF receptor. A c-met protooncogene
product possessing an intracellular tyrosine
kinase domain has been identified as a cel-
lular receptor for HGF (Bottaro et al 1991):
c-met is expressed in epithelial cells in vari-
ous organs, including type II pneumocytes
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in alveoli; since HGF is detected mostly in
mesenchymal or stromal cells, HGF is sug-
gested to act primarily as a mesenchymal
factor that affects the adjacent epithelia in
a paracrine manner during development and
affects other mesenchymal-epithelial inter-
actions (Sonnenberg et  al 1993, Panos et al
1993, Mason et al 1994, Shiratori et al
1995, Sato et al 1997). Expression of c-met
has been detected also in endothelial cells
(Bussolino et al 1992).
Effect of corticosteroids on HGF. In
vitro, corticosteroids suppress HGF expres-
sion in human lung fibroblasts and HGF
production in embryonic lung fibroblasts,
they suppress HGF mRNA expression and
HGF production in human skin fibroblasts
and production of HGF in bone marrow
stromal cells (Matsumoto et al 1992,
Matsunaga et al 1994, Takai et al 1997).
Growth factor-induced HGF mRNA ex-
pression and HGF secretion are inhibited
by dexamethasone (Gohda et al 1994). In
contrast, in the rat lung, c-met mRNA is
elevated by dexamethasone (Oshika et al
1998a, 1998b).
3.2.2. HGF and lung development
Expression of HGF and c-met. HGF and
c-met expression appear in virtually all of
HGF and c-met is already detectable in
human embryos at a gestational age of 6
weeks. HGF expression is not confined to
mesenchymal tissues but is expressed dur-
ing development in epithelial tissues, as
well (Wang et al 1994, Kolatsi-Joannou et
al 1997). In rats, HGF and c-met mRNA
levels are low during late gestation and the
neonatal period and increase markedly 3 ot
4 weeks postnatally; HGF is predominantly
expressed in stromal cells, and c-met in epi-
thelial cells in rats during late gestation and
the early neonatal period (Kagoshima et al
1992). HGF is suggested to play a role in
organ formation and maturation, and in the
maintenance of tissue homeostasis during
the postnatal period, presumably through
lung
HGF in lung injury. After pneumectomy
in mice, alveolar and airway epithelial cells
undergo compensatory DNA synthesis, and
HGF mRNA and protein levels parallel this
increase. The c-met expression in these mice
is localized predominantly in alveolar type
II and airway epithelial cells. Neutraliza-
tion of HGF by an antibody suppresses the
compensatory DNA synthesis in epithelial
cells, whereas administration of recombi-
nant HGF stimulates it, suggesting a
pulmotrophic role for HGF in lung regen-
eration (Sakamaki et al 2002). In induced
lung injury in rats, HGF increases in 3 to
14 days and peaks at 7 to 14 days, drop-
ping sharply after 2 weeks: The high levels
of HGF associate with bronchial and alveo-
lar epithelial cell proliferation (Adamson  et
al 1999). Moreover, HGF protein level, ex-
pression of HGF mRNA, and HGF activ-
ity increase parallel to the DNA synthesis
of alveolar epithelial cells. There also oc-
curs a transient expression of c-met, after
which it is down-regulated. Inhibition of
HGF reduces the DNA synthesis of alveo-
lar epithelial cells and aggravates lung in-
jury (Yanagita et al 1993, Yamada et al
2000). In humans, in acute lung injury, the
its potential to act as a paracrine mitogen,
motogen, and morphogen for epithelial cells
(Montesano et al 1991, Kagoshima et al
1992).
Mice lacking the HGF gene fail to com-
plete development. This mutation affects
the embryonic liver, which is reduced in size
and shows extensive loss of parenchymal
cells. The mice die in utero with signs of
apoptosis in their liver parenchymal cells.
HGF is also essential for the development
of several epithelial organs (Uehara et al
1995, Schmidt et al 1995). Mice lacking c-
met fail to complete organogenesis and die
with hypoplasia of the liver, leg muscles,
and diaphragm (Bladt et al 1995).
3.2.3. HGF and injury in the preterm
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HGF level is higher in the pulmonary
edema fluid than in the plasma, indicating
that the primary source of circulating HGF
is the lung (Vergheseet al 1998). These data
suggest that after acute lung injury, HGF
is newly produced in the lung and that HGF
is active in the alveolar space and may me-
diate early events in lung repair and play a
role in lung regeneration (Panos et al 1996,
Yanagita et al 1993, Vergheseet al 1998).
In contrast, in adult ARDS (adult respira-
tory distress syndrome) patients, high lev-
els of HGF are associated with poor prog-
nosis; one possible explanation is that in
ARDS, HGF may inhibit surfactant me-
tabolism (Stern et al 2000, Vivekananda et
al 2000).
Alveolar type-II cell proliferation occurs
in response to lung injury, and is thought
to play a critical role in alveolar epithelial
repair (Piedboeuf et al 1996, Daly et al
1998). For airway epithelial cells and alveo-
lar epithelial cells in vivo and in vitro, HGF
is a potent mitogen. Intravenous injection
of human recombinant HGF into mice with
acute lung injury stimulates DNA synthe-
sis of airway and alveolar epithelial cells
(Ohmichi et al 1996). Exogenous HGF acts
as a pulmotrophic factor in vivo in mice
with severe lung injury induced by
bleomycin and prevents the progression of
bleomycin-induced lung injury when ad-
ministered in either a simultaneous or de-
layed fashion (Yaekashiwa et al 1997). In-
tratracheal instillation of recombinant HGF
induces a time- and dose-dependent increase
in type II cell proliferation, although, in
animals exposed to hyperoxia, this increase
is less (Panos et al 1996). HGF may act as a
pulmotrophic factor responsible for airway
and alveolar regeneration during lung re-
generation after acute lung injury (Ohmichi
et al 1996). Intratracheal instillation of
HGF may, after lung injury, provide a po-
tential strategy to promote type II cell pro-
liferation and augment alveolar epithelial
repair (Panos et al 1996).
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- to evaluate the lung-lining fluid VEGF and the protein expression of VEGF and its
receptor Flt-1 during the perinatal period.
- to evaluate in preterm infants the role of VEGF in acute and chronic lung injury.
- to evaluate in preterm infants the lung-lining fluid HGF during the perinatal period
and in acute and chronic lung injury.
- to evaluate in preterm infants the effect of early prophylactic dexamethasone treat-
ment on concentrations of the lung-lining fluids VEGF and HGF.





All studies were done with the approval of
the Ethics Committee of the Hospital for
Children and Adolescents, University Cen-
tral Hospital, Helsinki.  The aim of Study
IV was to evaluate the effect of early post-
natal dexamethasone on severity of RDS and
development of BPD in preterm infants.
However, in multiple trials at the time, sev-
eral adverse effects from early dexametha-
sone treatment became evident, and its ef-
fect in reducing risk for BPD became con-
troversial (Bhuta et al 1998). The clinical
trial was therefore discontinued at the stage
at which only 30 preterm infants had been
enrolled.
1.2. Patients in tracheal aspirate studies
All the infants included were treated in the
neonatal intensive care unit of the Hospital
for Children and Adolescents, Helsinki
University Central Hospital. Those infants
enrolled were intubated at birth because of
failure to establish spontaneous ventilation
and all underwent mechanical ventilation
during the study period. Those with major
anomalies were excluded. All infants were
treated according to the standard protocols
of the neonatal intensive care unit. BPD was
defined, in all studies, as the need for supple-
mental oxygen at the age of 36 gestational
weeks, in association with chest radio-
graphic findings typical for BPD (Shennan
et al 1988).
1.2.1. Preterm infants
For Studies I, II, and III, a total of 70 in-
fants were enrolled between August 1993
and October 1997. Of these infants, six were
included in both Studies I and II. Patients
in Studies II and III were mostly the same;
patients were selected for these two studies
so that there were equal numbers of infants
developing BPD and surviving without
BPD. These groups were matched accord-
ing to gestational age and birth weight
(Table 1).
1.2.2. Term infants without primary lung
injury
Healthy term infants. Study II comprised
35 healthy term infants (18 males, 17 fe-
males, gestational age 39.5±2.3 wk, birth
weight 3478±482 g) from normal pregnan-
cies. Of these, 22 were intubated for tra-
cheal suctioning because of meconium-
stained amniotic fluid. In none of them was
any significant amount of meconium found
in the trachea. Of the other 13, blood
samples were taken together with samples
for clinical analyses during the first postna-
tal week.
Intubated term infants. Five other term
infants (3 males, 2 females, gestational age
38.9±2.2 wk, birth weight 3324±651 g)
who had cardiac anomalies without pulmo-
nary pathology and had cardiac surgery
during the first 10 postnatal days were en-
rolled between June 1998 and February
1999. A TAF sample was collected before
surgery. These infants had no prenatal com-
plications, and none had infections.
1.2.3. Infants in the dexamethasone study
This open-label study (IV), carried out be-
tween August 1997 and July 1999, com-
prised 30 preterm infants (19 males, 11 fe-
Material and methods
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males, gestational age 29.2±1.1 wk, birth
weight 1241±154 g) randomized to receive
dexamethasone (n=15) or to serve as con-
trols (n=15). Inclusion criteria were birth
weight 1000 to 1500 g and respiratory dis-
tress syndrome that required mechanical
ventilation and surfactant treatment. Dex-
amethasone, given as a 4-day course, was
started at the age of 12 to 24 hours at a
dose of 0.5 mg/kg/day for 2 days and 0.25
mg/kg/day for the subsequent 2 days (Study
IV, Table 1).
1.2.4. Infants with PPHN
For Study II, 23 infants with PPHN (12
males, 11 females, gestational age 37.2±3.8
wk, birth weight 3111±964 g) were en-
rolled between 1993 and 1997. PPHN was
diagnosed as Doppler ultrasound-confirmed
1 Pre-eclampsia: elevated maternal blood pressure and proteinuria.
2 PROM: Premature rupture of the membranes > 24 hrs ante partum.
3 Chorionamnionitis: clinical signs, leukocytosis (B-leuk>14x109/L), and C-reactive protein concentra-
tion in plasma >50mg/L.
4 1 week in Study I, 10 days in Study II, 2 weeks in Study III.
5 Bronchopulmonary dysplasia, defined as need for supplemental oxygen at 36 gestational weeks, in asso-
ciation with typical chest radiographic findings.
In Studies II and III, patients selected to include equal numbers of infants subsequently developing BPD and
those surviving without it.
Material and methods
Table 1. Patient data in preterm infants (Studies I to III)
Parameter Study
I (N=44) II (N=31)  III (N=32)
Prenatal
Antenatal betamethasone 36 (82%) 25 (81%) 28 (88%)
Pre-eclampsia 8 (18%) 7 (23%) 9 (28%)
PROM   or chorionamnionitis 16 (36%) 14 (45%) 14 (44%)
At birth
Mode of delivery (section/vaginal) 25 / 19 19 / 12 18 / 14
Gestational age (wks) 27.3 ± 2.0 26.7±1.8 27.0 ± 1.7
Birth weight (g) 962 ± 319 819 ± 167 906 ± 248
Gender (M / F) 23 / 21 16 / 15 18 / 14
Apgar score 1 min 5 ± 2 5 ± 2 5 ± 2
Umbilical cord pH 7.26 ± 0.11 7.26 ± 0.12 7.28 ± 0.12
Umbilical cord base excess -3.9 ± 3.9 -3.5 ± 3.7 -3.3 ± 4.0
Postnatal
Initial arterial / alveolar ratio 0.21 ± 0.14 0.23 ± 0.20 0.21 ± 0.12
Surfactant therapy 35 (80%) 24 (77%) 25 (78%)
Doses of surfactant 3 ± 1 3 ± 1 2 ± 1
Indomethacin therapy 34 (77%) 27 (87%) 28 (88%)
Postnatal dexamethasone during study period 3 (7%) 7 (23%) 6 (19%)
Mean inhaled oxygen during during study period (%) 34 ± 15 35 ± 15 35 ± 13
Duration of mechanical ventilation (d) 16 ± 14 24 ± 18 22 ± 18
BPD 13 (30%) 16 (52%) 17 (53%)









iso- or suprasystemic pulmonary artery pres-
sure and persistent hypoxia despite optimal
conventional therapy.
1.3. Patients in immunohistochemistry studies
Subjects for immunohistochemistry stud-
ies were collected between 1985 and 1999.
Of the 14 infants, 7 were born prematurely:
3 of these died of acute respiratory distress
syndrome during the first postnatal week
and 4 of bronchopulmonary dysplasia. Of
the 7 term infants, 4 died of cardiac anoma-
lies and 2 of PPHN, and a lung biopsy was
obtained from an infant suffering alveolar-
capillary dysplasia. In addition, the 4 fe-
tuses enrolled were aborted because of ma-
jor extrapulmonary anomalies; all had mi-
croscopically and macroscopically normal
lungs. None of the infants had pneumonia
at the time of death. Those term infants who
died of congenital cardiac anomalies had
macroscopically and microscopically normal
lungs. (Study II, Table 1).
2. Methods
2.1. Sample collection
TAF. Samples of tracheal aspiration fluid
(TAF) were collected once daily by
standardised routine tracheal lavage. One
mL of sterile isotonic saline was instilled
into the endotracheal tube, the patient was
manually ventilated for 3 breaths, and the
trachea was suctioned twice for 5 seconds.
For analysis of tracheal aspirates, secretions
were collected into a trap and transferred
into tubes containing 500 I.U. of aprotinin
(Trasylol®, Bayer, Leverkusen, Germany)
and 5 mg of deferoxiamine (Desferal®,
Ciba, Basel, Switzerland). The tubes were
stored at -20°C until analysis.
In Studies I and II, a total of 341 TAF
samples were collected from 69 preterm
infants during their first 10 postnatal days.
In Study II, 27 samples were collected dur-
ing postnatal weeks 3 to 5 from 8 infants
who developed BPD; from 22 healthy term
infants came 22 samples taken at birth; from
5 intubated term infants with cardiac
anomalies and without primary lung injury,
9 samples during the first 10 postnatal days;
and from 12 PPHN infants, 54 samples
during the first 10 postnatal days. In Study
III, 172 TAF samples were collected from
32 preterm infants during the first 2 post-
natal weeks. In Study IV, 41 samples were
collected from 15 infants in the dexametha-
sone group, and 49 samples from 15 infants
in the control group during the first post-
natal week.
Plasma. In Study I, 24  blood samples
were taken from 9 preterm infants through
radial artery catheters into EDTA tubes. In
Study II, 13 blood samples were taken from
13 healthy term infants from peripheral
veins and 29 blood samples from 11 PPHN
infants through peripheral arterial catheters
into EDTA tubes. All tubes were centri-
fuged (3000 rpm for 10 min), and plasma
was stored at -20°C until analysis.
2.2. Assays from tracheal aspirate samples
All assays from tracheal aspirate samples
were performed in the Scientific Laboratory
in the Hospital for Children and Adoles-
cents, University of Helsinki.
VEGF and HGF. VEGF was analyzed
by the Quantikine Human VEGF Immu-
noassay (R&D Systems, Oxon, UK). HGF
in TAF was analyzed by the Quantikine Hu-
man HGF Immunoassay (R&D Systems,
Oxon, UK).
Analyses for dilution of the samples.
In Study I, a correction for dilution of
samples was calculated by using the ratio
of urea-N in TAF and in each correspond-
ing serum sample.
For Studies II to IV, in order to elimi-
nate the effect of dilution of TAF samples,
the concentration of the secretory compo-
nent of immunoglobulin-A (IgA-SC) was
determined by direct ELISA. Concentration
29
of IgA-SC in lung secretions is independent
of capillary leakage, and the concentration
of IgA-SC in tracheal aspirates is indepen-
dent of respiratory distress, gestational age,
or postnatal age (Watts et al 1992). Secre-
tory IgA isolated from human colostrum
served as the standard, and the results were
standardised with the help of Dr. B. Götze-
Speer and Prof. Ch. Speer (University
Children’s Hospital, Wyrzburg, Germany).
Microtiter plates (Nunc, Roskilde, Den-
mark) were coated overnight at +4°C with
100-µL aliquots of 1:2000 diluted anti-hu-
man secretory component (Dako, Glostrup,
Denmark) in 50 mM Na bicarbonate, pH
9.5. After washing with 200 µL of 20-mM
tris-500 mM NaCl, pH 7.5 (TBS), the
plates were blocked for unspecific protein
binding by incubation with 200 µL of 2%
bovine serum albumin (BSA) in TBS and
washed with 0.05% Tween 20 in TBS
(TTBS). TAF samples were diluted to be-
tween 1:10 to 1:500 in diluting buffer (1%
BSA in TTBS), and 100-µL aliquots were
added to the wells. After incubation over-
night at room temperature, the plates were
washed 3 times with TTBS; 100 µL of per-
oxidase-conjugated rabbit anti-human SC
(Dako), diluted 1:400 in diluting buffer,
was added, and the plates were incubated
for 4 hours at room temperature. After
washing with TTBS, the plates were devel-
oped with 100 µL of substrate solution con-
taining 8 mg of orthophenylenediamine
(Dako) and 5 µL of 30% H2O2 in 12 mL
water. After 30 minutes at room tempera-
ture, the optical densities of the plates were
read at 450 nm.
Measurements for surfactant matu-
rity. In Study I, a tracheal aspirate sample
was taken within 3 hours postnatally, be-
fore the infants’ treatment with surfactant
for determination of the lecithin/sphingo-
myelin ratio (LS-ratio), and presence of
ceramide lactoside (Rauvala et al 1984,
Hallman et al 1989).
2.3. Immunohistochemistry
All immunostainings were performed in the
Haartman Institute Laboratory, University
of Helsinki. Autopsies were performed
within 2 days after death. The samples were
fixed in 10% neutral buffered formalin,
embedded in paraffin, and kept in dry stor-
age at room temperature. After sectioning,
the slides were used for immunoperoxidase
stainings within 2 weeks. For stainings, af-
ter drying overnight at 37°C, 4- or 5-µm
sections were cut on coated slides, deparaf-
finized, and rehydrated. The sections were
either treated with trypsin or microwaved.
Endogenous peroxidase was quenched by
incubating the sections in methanol and
hydrogen peroxidase. After applying block-
ing serum, the sections were incubated over-
night at +4°C with the primary antibody.
Immunohistochemical stainings were per-
formed by use of commercial rabbit, goat,
or mouse Elite ABC kits (Vectastain, Vec-
tor Laboratories, Burlingame, CA, USA).
The following day, the sections were incu-
bated with the biotinylated secondary an-
tibody and the peroxidase-labeled ABC for
30 minutes each. Bound peroxidase was vi-
sualized by incubation in a 3-amino-9-
ethylcarbazole (AEC) solution (Sigma A-
5754). Finally, the sections were stained
with hematoxylin. Antibodies used were:
VEGF: A-20, Santa Cruz, 1:100 dilution,
and Flt-1: C17, Santa Cruz sc 316, 1:100
dilution. A negative control was included
in each staining round. In these slides, stain-
ing was performed by the identical proto-
col without primary antibody.
2.4. Statistical analyses
In all studies, patient data are given as
mean±SD, and results as mean±SEM.
When data were not normally distributed,
logarithmic transformations of the data were




sidered statistically significant. All calcu-
lations were done with StatView 4.1 (I) or
StatView 5.0 (II-IV).
Study I. Kruskal-Wallis one-way
ANOVA and the Mann-Whitney U-test
served for analyses between concentrations
of VEGF in TAF and categorical variables.
Simple regression analysis was used for
analyses between concentrations of VEGF
in TAF and continuous variables. The chi-
square served for analyses between categori-
cal variables. The Bonferroni correction
served for post-hoc comparisons.
Study II. One-way ANOVA and
Student’s t-test served for analyses between
concentrations of VEGF in TAF and cat-
egorical variables. Simple regression analy-
sis was used for analyses between concen-
trations of VEGF in TAF and continuous
variables. The Bonferroni correction served
for post-hoc comparisons.
Study III. One-way ANOVA and
Student’s t-test served for analyses between
concentrations of HGF in TAF and categori-
cal variables. Simple regression analysis was
used for analyses between concentrations of
HGF in TAF and continuous variables. A
multiple regression analysis was performed
using concentration of HGF as the depen-
dent variable and all significant univariate
repeated-measurements-adjusted correla-
tions as independent variables. The chi-
square was used for analyses between infants
developing BPD and those surviving with-
out BPD in categorical variables. The
Bonferroni correction served for post-hoc
comparisons.
Study IV. One-way ANOVA and
Student’s t-test served for analyses between
concentrations of VEGF or HGF in TAF and
categorical variables. Simple regression
analysis was used for analyses between con-
centrations of VEGF or HGF in TAF and
continuous variables. Student’s t-test was
used in analyses of differences between the
dexamethasone group and the control group
in continuous variables. The chi-square test
served for analyses between the dexametha-
sone group and the control group for cat-
egorical variables. The Bonferroni correc-
tion served for post-hoc comparisons.
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1. VEGF during the perinatal period
(Studies I and II)
VEGF in TAF in preterm infants. The
mean concentration of VEGF in TAF in-
creased from 25±12 pg/mL on the first day
to 526±120 pg/mL on day 7. In Study I, a
correction for dilution of the tracheal aspi-
rates was performed in 69 of the 189
samples. In these samples, the actual mean
concentrations of VEGF were estimated to
be 4.1±0.9 ng/mL during days 1 to 3, and
16.3±2.3 ng/mL during days 4 to 7. In
Study II, the secretory component of im-
munoglobulin A (IgA-SC) was measured,
and data were corrected for dilution by ad-
justment with IgA-SC before all statistical
analyses. The dilution-adjusted mean con-
centration of VEGF at birth for preterm
infants was 4±2 pg/mL/IgA-SC unit on day
1, and 65±17 pg/mL/IgA-SC unit on day
10, and the mean concentration of VEGF
during the first 10 postnatal days was 54±6
pg/mL/IgA-SC (Study II, Figure 2).
In preterm infants, no correlations were
seen between VEGF in TAF and gestational
age or birth weight. Mean VEGF correlated
inversely with Apgar score, and with pH
and base-excess in blood-gas analysis from
the umbilical cord artery. In preterm infants
born to mothers with premature rupture of
the membranes or with chorionamnionitis,
or with both, VEGF was higher and in
preterm infants born to mothers with pre-
eclampsia lower than in preterm infants
without these antenatal complications. In
32 preterm infants, a tracheal aspirate
sample was obtained within 3 hrs after birth
for determination of surfactant maturity. In
these samples, the LS-ratio showed a corre-
lation with VEGF. In 7 of these 32 infants,
ceramide lactoside was present, and they had
higher VEGF. The presence of ceramide
lactoside was associated with premature
rupture of the membranes and with
chorionamnionitis (P=0.0026) (Table 2).
VEGF in TAF in term infants with-
out primary lung injury. For healthy term
infants, the mean concentration of VEGF
at birth was 4±1 pg/mL (dilution-adjusted
mean concentration 0.5±0.2 pg/mL/IgA-SC
unit). For intubated term infants, the mean
concentration of VEGF during the first 10
postnatal days was 434±246 pg/mL (dilu-
tion-adjusted mean concentration 13.7±8.6
pg/mL/IgA-SC unit) (Study II, Figure 2).
VEGF in plasma. The mean concentra-
tion of VEGF in plasma during the first
postnatal week was for preterm infants 48±6
pg/mL, and for healthy term infants
138.5±39.4 pg/mL (Study II, Figure 2).
VEGF immunohistochemistry. For
VEGF in fetuses and in premature infants,
positive immunostaining was apparent in
bronchial epithelial cells, in cuboidal cells
in the alveolar epithelium, and in vascular
endothelial cells; in addition, some alveo-
lar macrophages were positive. In term in-
fants, VEGF staining was visible in bron-
chial epithelial cells and in alveolar mac-
rophages (Study II, Figure 1).
Flt-1 immunohistochemistry. In fe-
tuses, positive staining was apparent in cap-
illaries, veins, and small arteries in the en-
dothelial cells, and in the intima of the small
arteries, and a staining reaction was visible
in alveolar epithelium in bronchial epithe-
lial cells and cuboidal cells. In premature
infants, a similar staining reaction was vis-
ible in vessels and bronchi. In term infants,
positive staining for Flt-1 was seen in the
endothelial lining of veins and capillaries
and arteries, as well as in the intima of the
small arteries, and in bronchial epithelial
Results
cells (Study II, Figure 1).
2. VEGF in lung injury in preterm
infants (Studies I and II)
VEGF in TAF and parameters of respi-
ratory distress. In Studies I and II, al-
though no correlation existed between ini-
tial arteriolar-alveolar ratio and VEGF, pa-
tients who required surfactant therapy had
lower VEGF than those who survived with-
out surfactant. Moreover, an inverse corre-
lation also appeared between mean VEGF
and number of surfactant doses required. In-
verse correlations existed between VEGF
and both mean inspiratory oxygen and du-
ration of mechanical ventilation. In neither
study was any difference found in VEGF
concentrations between patients receiving
1 Pre-eclampsia: maternal elevated blood pressure and proteinuria (vs infants without maternal com-
plications).
2 PROM: Premature rupture of the membranes > 24 hrs ante partum.
3 Chorionamnionitis: clinical signs, leukocytosis (B-leuk>14x109/L), or C-reactive protein concentra-
tion in plasma >50mg/L.
4 vs. infants without maternal complications.
5 Lecithin/sphingomyelin ratio, measured from tracheal aspirate sample obtained within 3 hrs after
birth.
- Data unavailable.
glucocorticoid treatment (antenatal or post-
natal) or not (Table 3).
VEGF in TAF in infants developing
BPD. In Study I, during days 4 to 7, those
13 patients who developed BPD had a lower
mean VEGF than those surviving without
BPD (Figure 2, Table 3). In Study II,
preterm infants who developed BPD had
lower VEGF in TAF during the first 10
postnatal days than did those who survived
without it, but this difference did not reach
statistical significance (Table 3). In Study
II, for those 8 BPD infants there was a ten-
dency towards lower VEGF concentrations
during weeks 3 to 5 than during first 10
postnatal days (33.4±3.6 pg/mL / IgA-SC
unit vs. 49.6±9.1 pg/mL / IgA-SC unit,
P=0.061).
VEGF and Flt-1 immunohistochem-
Patrik Lassus
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Table 2. VEGF in TAF and perinatal factors in preterm infants (Studies I and II)
Parameter Study I Study II
(pg/mL) (pg/mL/IgA-sc unit)
D 1-3 D 4-7 D 1-10
Prenatal
Antenatal betamethasone NS NS NS
Pre-eclampsia NS 88±18 vs 308±50; P=0.0001 NS
PROM  or chorionamnionitis NS 504±68 vs 308±50; P=0.0058 NS
At birth
Gestational age (wks) NS NS NS
Birth weight (g) NS NS NS
Apgar score 1 min R=-0.30, P=0.012 P=-0.28, R=0.0028 NS
Umbilical cord pH NS NS R=-0.36, P=0.050
Umbilical cord base excess R=-0.46, P=0.0084 R=-0.30, P=0.024 R=-0.54, P=0.0001
LS-ratio R=0.29, P=0.031 NS -







istry in infants developing BPD. Posi-
tive immunostaining for VEGF appeared in
BPD infants in bronchial epithelial cells and
alveolar macrophages, in vascular endothe-
lium, and in cells apparently representing
type-II pneumocytes. For Flt-1, in BPD
infants, positive staining was visible
throughout the walls of small arteries, and
in the endothelial lining of veins and capil-
laries. In addition, bronchial epithelium was
positive, as were cells apparently represent-
ing type-II pneumocytes in the alveoli, and
alveolar macrophages (Study II, Figure 1).
VEGF in PPHN-infants. In PPHN in-
fants, the mean concentration of VEGF in
TAF during the first 10 postnatal days was
205±30 pg/mL (dilution-adjusted mean
concentration 19.6±3.5 pg/mL/IgA-SC unit
vs. 13.7±8.6 pg/mL/IgA-SC unit in intu-
bated term infants without primary lung
injury; P=0.10). In plasma, the mean con-
centration of VEGF for PPHN infants was
43.5±6.7 pg/mL vs. 138.5±39.4 pg/mL in
healthy term infants, P=0.039) (Study II,
Figure 2).
In immunohistochemistry in PPHN in-
fants, staining for VEGF was apparent in
bronchial epithelium and vascular endot-
helial cells. Additional staining was visible
in cells apparently representing type-II
pneumocytes in alveolar epithelium. In the
infant with alveolar-capillary dysplasia,
strong staining appeared in bronchial epi-
thelium and vascular endothelial cells; also
alveolar macrophages were positive. In
PPHN infants and in the infant with al-
veolar-capillary dysplasia, staining for Flt-
1 was apparent throughout the vascular
walls in capillaries, arteries, and veins. Bron-
Table 3. VEGF in TAF and parameters of respiratory distress (Studies I and II)
Parameter Study I Study I Study II
days 1 to 3 days 4 to 7 days 1 to 10
(pg/mL) (pg/mL) (pg/mL/IgA-sc unit)
Surfactant therapy  (+ vs -) NS 290±34vs653±135, P=0.0025 36±4vs97±27, P=0.0011
Doses of surfactant R=-0.26,P=0.034 R=-0.35, P=0.0022 R=-0.26, P=0.0077
Dexamethasone therapy (+ vs -) NS NS NS
FiO2 (%) NS R=-0.29, P=0.0092 NS
Duration of intubation (d) NS NS R=-0.25, P=0.01
BPD (+ vs -) NS 235±31vs383±50, P=0.016 46±7vs64±17, P=0.28
1
2
1 FiO2: Mean supplemental oxygen during study period.
2 Defined as need for supplemental oxygen at 36 gestational weeks, in association with typical chest
radiographic findings.
Mean VEGF concentrations in TAF during post-
natal days 4-7 in preterm infants developing BPD























chial epithelium and cells apparently rep-
resenting type-II pneumocytes in alveolar
epithelium were positive, as well as alveo-
lar macrophages (Study II, Figure 1).
3. HGF during the perinatal period
and in lung injury in preterm infants
(Study III)
HGF in TAF and perinatal parameters.
In preterm infants, the mean concentration
of HGF was 1113±597 pg/mL on the first
postnatal day, 981±382 pg/mL on day 14,
and 619±64 pg/mL during the first 2 post-
natal weeks. IgA-SC, the secretory compo-
nent of immunoglobulin A, was measured,
and data were corrected for dilution by ad-
justment with IgA-SC before analysis. The
dilution-corrected values were: day 1,
80.5±27.3 pg/mL/IgA-SC unit; day 14,
50.2±16.37 pg/mL/IgA-SC unit; and dur-
ing the first 2 postnatal weeks, 71.4±15.7
pg/mL/IgA-SC unit.
No differences existed between mean
concentrations of HGF during the first 2
postnatal weeks in patients born to moth-
ers with premature rupture of the mem-
branes or with chorionamnionitis, in pa-
tients born to mothers with pre-eclampsia,
or in infants without these maternal com-
plications. Of the mothers of these infants,
28 received treatment with an antenatal
glucocorticoid, and the number of treat-
ments correlated negatively with mean
HGF concentration (R=-0.22, P=0.021).
During the first 2 postnatal weeks, mean
HGF correlated negatively with gestational
age (R=-0.32, P=0.0001), but not with
birth weight. No correlations existed be-
tween mean HGF during the first 2 post-
natal weeks and  1’ and 5’-minute Apgar
scores, or base-excess and pH in blood-gas
analysis from the umbilical cord artery
(Study III, Table 2).
HGF in TAF and parameters of res-
piratory distress. Those 7 infants surviv-
ing without surfactant therapy had higher
mean HGF concentrations than did those
needing surfactant (145.9±49.6 pg/mL/
IgA-SC unit vs. 49.6±13.7 pg/mL/IgA-SC
unit; P=0.0001). A tendency toward a nega-
tive correlation existed between mean HGF
concentration and number of surfactant
doses required (R=-0.16, P=0.06), and be-
tween HGF and duration of mechanical
ventilation. No association appeared be-
tween mean HGF concentration and need
for postnatal dexamethasone, or between
mean HGF concentration and indometha-
cin treatment (Study III, Table 2).
HGF in TAF and development of
BPD. The 15 infants who survived with-
out BPD showed higher mean HGF con-
centrations during the first 2 postnatal
weeks than did those who subsequently
developed BPD (101.8±31.9 pg/mL/IgA-
SC unit vs. 44.5±8.9 pg/mL/IgA-SC unit,
P=0.028 (Study III, Figure 1 and Table 2).
4. Effects of dexamethasone on VEGF
and HGF (Study IV)
Dexamethasone and clinical parameters.
In the dexamethasone group, less BPD was
observed (1/15 vs. 7/15 in control group,
P=0.01), but no differences existed between
dexamethasone and control groups in regard
to other perinatal parameters
Because TAF samples were not available
every day from every patient, the mean val-
ues on postnatal days 1 to 2, 3 to 4, and 5
to 7 served for analysis. The secretory com-
ponent of immunoglobulin A (IgA-SC) was
measured, and data were corrected for dilu-
tion by adjustment with IgA-SC before
analysis.
Dexamethasone and VEGF. No differ-
ences existed between the dexamethasone
and control groups in mean VEGF levels
on days 1 to 2 (18.4±7.5 vs. 14.8±5.0 pg/
mL/IgA-SC unit, respectively, P=0.70), on
days 3 to 4 (35.4±5.6 vs. 38.7±10.7 pg/
mL/IgA-SC unit, P=0.77), or on days 5 to
7 (48.8±9.0 vs. 37.9±9.0 pg/mL/IgA-SC
unit, P=0.45) (Study IV, Figure 1).
Dexamethasone and HGF. No differ-
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ences existed in mean HGF concentrations
between the dexamethasone and control
groups on days 1 to 2 (62±8 vs. 110±32,
pg/mL/IgA-SC unit, respectively, P=0.16).
The dexamethasone group had a lower mean
HGF concentration than the control group
on days 3 to 4 (41±5 vs. 96±20 pg/mL/IgA-
SC unit, respectively, P=0.0022) and on
days 5 to 7 (47±11 vs. 123±49 pg/mL/IgA-
SC unit, P=0.030) (Study IV, Figure 1).
Infants who had received antenatal
betamethasone had a tendency towards a
lower mean HGF on days 1 to 2 than did
those given no betamethasone (69±11 vs.




1. VEGF and lung development
VEGF plays a pivotal role during fetal de-
velopment: inactivation of even a single
VEGF allele in mice results in early em-
bryonic lethality: development of vascular
endothelial cells is blocked, and the forma-
tion of blood vessels is abnormal, includ-
ing the pulmonary vasculature (Carmeliet
et al 1996, Ferrara et al 1996, Bautch et al
2000, Ng et al 2001). VEGF plays a role,
in addition to development, also postnatally,
in physiological angiogenesis and in vascu-
lar maintenance (Leung et al 1989, Pepper
et al 1991, Shifren et al 1994). The concen-
trations of VEGF in TAF in our studies in
preterm infants fell into the same range as
that shown in vitro to induce proliferation
and differentiation of human fetal airway
epithelial cells (Acarregui et al 1998). The
level of VEGF in almost all infants studied
was low after birth but increased steadily
during the early postnatal period. Its con-
centrations in TAF correlated neither with
gestational age nor with birth weight, but
VEGF levels were higher at birth and dur-
ing the first 10 postnatal days in preterm
than in term infants. Moreover, we discov-
ered a correlation between the functional
maturity of alveolar type II cells, defined as
the LS-ratio, in a TAF sample (Rauvala et
al 1984), and VEGF in TAF, suggesting that
concentration of VEGF may reflect the func-
tional maturity of the preterm lung.
We found constant expression for VEGF
in all fetuses and infants in bronchial epi-
thelium and alveolar macrophages, and in
addition, in fetuses and preterm infants also
in alveolar epithelium. Pulmonary VEGF
expression during development has been
found by immunohistochemistry in
nonendothelial cells including alveolar and
bronchial epithelial cells and alveolar mac-
rophages, and in smooth muscle cells in-
cluding those lining blood vessels (Shifren
et al 1994, Brogi et al 1996, Acarregui et
al 1999, Bhatt et al. 2001). In situ hybrid-
ization has shown pulmonary VEGF expres-
sion during development most strongly in
alveolar epithelial cells but also in bronchial
epithelial cells and smooth muscle cells
(Hirose et al 2000, Bhatt et al 2001). Pul-
monary Flt-1 staining during development
has been found in immunohistochemistry
mainly in vascular endothelium (Peters et
al 1993), and for Flt-1, we found positive
staining in endothelial cells lining capillar-
ies, veins, and small arteries. Moreover, we
discovered that VEGF level was signifi-
cantly higher in TAF than in plasma in
preterm infants. These data, in line with
previous findings, suggest a paracrine role
for VEGF, secreted by nonendothelial cells
and modulating activities in adjacent vas-
cular endothelium.
In contrast to previous findings, we found
additional staining for VEGF in the vascu-
lar endothelium in fetuses and in preterm
infants and for Flt-1 in bronchial epithelial
cells in fetuses and in infants. One explana-
tion for these surprising results may be due
to nonspecific staining during immunohis-
tochemistry. A negative control, in which
staining was performed by an identical pro-
tocol without a primary antibody, was in-
cluded in each staining round, and in these
slides no staining was apparent. It is pos-
sible, however, that the polyclonal antibod-
ies we used (for VEGF, Santa-Cruz A-20,
and for Flt-1, Santa-Cruz C-17) exhibit
some nonspecific binding properties. Other
antibodies directed against these proteins
could be used for comparative stainings




control. On the other hand, in situ hybrid-
ization could be used to confirm the cells
that produce the respective RNAs. One
likely explanation for VEGF staining in the
endothelium may be that in these cells the
ligand is bound to its receptor.
The persistent appearance of VEGF and
Flt-1 during the perinatal period from the
16th gestational week supports a pivotal
role for VEGF in the development of the
human lung. We suggest that the pulmo-
nary VEGF level in preterm infants may be
gestational-age dependent and that the in-
crease in early postnatal VEGF in preterm
and term infants may represent a physio-
logical phenomenon belonging to the early
neonatal period.
2. VEGF in lung injury in preterm
infants
Antenatal complications. We detected
lower VEGF in TAF postnatally in preterm
infants from mothers with pre-eclampsia.
Similarly, in pregnancies complicated by
pre-eclampsia, VEGF mRNA levels in the
placentas are lower (Cooper et al 1996). In
premature infants and in fetal growth re-
striction, pre-eclampsia correlates with low
concentrations of surfactant protein A and
with a higher incidence of RDS (Schiff et al
1993, Kari et al 1995, Odegård et al 2000).
Our finding of lower VEGF may be related
to the postnatal respiratory difficulties seen
in these infants, because VEGF induces sur-
factant protein expression in fetal alveolar
epithelial cells in vitro and in vivo
(Acarregui et al 1998, Compernolle et al
2002).
We found higher VEGF in TAF in
preterm infants from pregnancies compli-
cated by chorionamnionitis, and in addition,
in tracheal aspirates, found ceramide
lactoside, a marker for the presence of neu-
trophils indicative of antenatal infection
(Hallman et al 1989), to be associated with
high pulmonary VEGF. Chorionamnionitis
has been associated with less severe RDS,
and this effect has been ascribed to the ef-
fect of prenatal inflammation in accelerat-
ing lung maturation and in possible induc-
tion of the surfactant system (Watterberg
et al 1996, Kitajima et al 1992). In experi-
mental animals, pulmonary VEGF expres-
sion is induced by proinflammatory media-
tors (Pertovaara et al 1994, Brogi et al
1994), many of which have been shown to
be higher in the lungs of preterm infants
born to mothers with premature rupture of
the membranes or with chorionamnionitis.
(Groneck et al 1994, Watterberg et al
1996). Because pulmonary VEGF expres-
sion is induced by proinflammatory media-
tors (Pertovaara et al 1994, Brogi et al.
1994) it therefore seems that inflammation
and infection also in preterm infants may
raise pulmonary VEGF levels.
Hypoxia is a major stimulator of VEGF
expression (Shweiki et al 1992). We found
that in preterm infants, asphyxia at birth
was associated with higher VEGF in TAF.
Hyperoxia reduces pulmonary expression of
VEGF in rats with hyperoxia-induced lung
injury, and its expression increases during
recovery to normoxia (Maniscalco et al
1995, Maniscalco et al 1997). We found an
inverse correlation between mean inspira-
tory oxygen and VEGF in TAF in preterm
infants postnatally. On the basis of our
present data, it appears possible that in the
lung of the preterm infant, hypoxia and
hyperoxia both affect VEGF levels.
Lung injury. We discovered in preterm
infants high pulmonary concentrations of
VEGF during the end of the first postnatal
week. In RDS, acute lung injury begins to
resolve within the first postnatal days, after
which a recovery phase usually begins
(Verma 1995). In premature infants with
RDS, pulmonary events associated with
development of chronic lung injury, includ-
ing enhanced pulmonary inflammation, are
suggested to occur during the recovery
phase at the end of the first week (Merritt
et al 1983, Watts et al 1992, Groneck et al
1994). We found that in preterm infants
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with more severe RDS (defined as lower
initial arterial/alveolar ratio, greater need
for surfactant, higher mean inspiratory oxy-
gen, and longer duration of mechanical ven-
tilation), VEGF in TAF was lower. In ani-
mal studies, VEGF has been suggested to
participate in repair of lung injury and in
protection of the lung against injury. Loss
of HIF-2-a, a promoter for VEGF, causes
fatal RDS in neonatal mice; in these mice,
intrauterine or postnatal intratracheal in-
stillation of VEGF stimulates surfactant
production, improves lung function, and
protects against RDS (Compernolle et al
2002). Prolonged exposure to hyperoxia in
animals results in a decrease in VEGF
(Johnston et al 1996, Klekamp et al 1999).
Hyperoxia itself may explain our finding,
or another explanation may be that infants
with severe pulmonary injury may be inca-
pable of responding to the inflammatory
stimuli with an increase in VEGF. Because
our data, however, suggest that the lower
pulmonary VEGF in preterm infants asso-
ciates with more severe RDS, VEGF may
play a protective or a reparative role in neo-
natal lung injury in addition to its role in
human lung development .
We found that preterm infants subse-
quently developing BPD had lower VEGF
during the early postnatal period. Immu-
nohistochemistry for VEGF and Flt-1
showed staining in type-II pneumocytes in
alveolar epithelium only in infants with
BPD. Rabbits recovering from hyperoxic
lung injury have type-II pneumocytes ex-
clusively expressing VEGF mRNA; this
suggests a role for VEGF in the regulation
of microvascular endothelial cell prolifera-
tion after oxidant injury (Maniscalco et al
1997). Thus, the presence of VEGF in the
alveolar epithelium of our infants with BPD
may be associated with the healing process.
Arrest of lung development. A signifi-
cant change has occurred in the epidemiol-
ogy and pathophysiology of BPD. The clas-
sical severe form of BPD has become less
common, replaced by less severe forms of
lung disease that affect the smallest preterm
infants (Charafeddine et al 1999, Parker et
al 1992, Rojas et al 1995). A newborn of
24 gestational weeks suffers from pulmo-
nary prematurity: there are no alveoli yet
present, surfactant production is just start-
ing, and the capillary bed is poorly devel-
oped. The pathological pulmonary findings
in infants with fatal BPD include a consis-
tent lack of significant alveolarization, and
a thickened alveolar septa resulting in em-
physematous-looking lungs (Chambers et
al 1989, Hislop et al 1990, Van Lierde et al
1991, Margraf et al 1991, Husain  et al
1998). In addition, capillaries do not de-
velop normally (Bhatt et al 2001). Inhibi-
tion of capillary growth, a central event
during septation and alveolar maturation,
may affect alveolarization in very premature
infants and result in the pathological find-
ings in infants with fatal BPD (Abman
2001). The pathogenesis of new BPD in
very immature preterm infants has there-
fore been suggested to be caused primarily
by arrest of normal lung development (Jobe
1999) and our finding of lower pulmonary
VEGF during the early neonatal period in
preterm infants developing BPD supports
this hypothesis.
3. HGF during the perinatal period
and in lung injury in preterm infants
HGF and lung development. We discov-
ered in TAF in preterm infants significant
amounts of HGF, the level of HGF postna-
tally in our preterm infants did not increase.
However, we found higher HGF in TAF
from more immature infants. HGF, a mes-
enchymal-derived growth factor for epithe-
lial cells, is suggested to participate in or-
gan formation and maturation during fetal
development (Montesano et al 1991,
Kagoshima et al 1992). In the lung, HGF
elicits mitogenic and morphogenic actions
in fetal alveolar type II cells and bronchi-
olar epithelial cells (Itakura et al 1997, Sato
et al 1997). Addition of HGF stimulates
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branching morphogenesis in alveolar and
bronchial epithelia of the fetal rat lung, and
HGF inhibition assays result in decreased
epithelial branching (Ohmichi et al 1998a,
1998b). The rapid postnatal increase in
HGF and c-met mRNA reported in neona-
tal rats suggests a role for HGF in lung de-
velopment also postnatally (Kagoshima et
al 1992). Our finding of a significant
amount of lung-lining fluid HGF in hu-
man preterm infants supports a role for
HGF in lung development.
Lung injury. In our study, infants with
more severe RDS had lower HGF concen-
trations in TAF. This may represent an im-
paired response to the stimuli induced by
lung injury, or it may be explained by dam-
age to the cells producing HGF, or it may
represent an insufficient capability of the
immature lung to respond to lung damage.
Acute respiratory distress is characterized
by diffuse lung damage and alveolar epi-
thelial injury (Piedboeuf et al 1996, Daly
et al 1998). In experimental animals suffer-
ing acute lung injury, expression of HGF
mRNA and HGF activity increase, and the
HGF concentration in lung lavage fluid
increases, both of which actions are associ-
ated with both bronchial and alveolar epi-
thelial cell proliferation. In these animals,
inhibition of HGF reduces the DNA syn-
thesis of alveolar epithelial cells and aggra-
vates the lung injury (Yanagita et al 1993,
Adamson et al 1999, Yamada et al 2000).
After pneumectomy in mice, neutralization
of HGF suppresses the compensatory DNA
synthesis in epithelial cells, whereas admin-
istration of recombinant HGF stimulates it
(Sakamaki et al 2002). These data suggest
that after acute lung injury, HGF produc-
tion is augmented and that HGF as a
pulmotrophic factor may mediate airway
and alveolar regeneration in lung repair.
BPD. In our study, those infants who
developed BPD had less HGF in TAF than
did those who survived without BPD. In-
travenous injection of human recombinant
HGF stimulates DNA synthesis of airway
and alveolar epithelial cells and prevents
injury progression (Ohmichi et al 1996,
Yaekashiwa et al 1997), and intratracheal
instillation of recombinant HGF induces a
time- and dose-dependent increase in type
II cell proliferation (Panos et al 1996). We
therefore suggest that since HGF is a
pulmotrophic factor responsible for alveo-
lar regeneration during lung repair, it plays
a role in repair in lung injury also in hu-
man preterm infants; we further suggest
that a relative lack of HGF may impair al-
veolar repair and thus contribute to the de-
velopment of BPD.
4. Dexamethasone and VEGF and
HGF
Dexamethasone and VEGF. Corticoster-
oids downregulate VEGF expression in vitro
(Nauck et al 1997, Horiuchi et al 1997,
Klekamp et al 1997), but in preterm in-
fants, postnatal dexamethasone may raise
VEGF levels in TAF (D'Angio et al 1999,
Bhatt et al 2000). We found no differences,
however, in concentrations of VEGF in TAF
in preterm infants who were randomized to
receive dexamethasone or not. More stud-
ies are therefore needed to evaluate in
preterm infants the effect of corticosteroids
on pulmonary VEGF in vivo.
Dexamethasone and HGF. We found
lower HGF in TAF from preterm infants
randomized to receive dexamethasone, in
line with in vitro studies, showing that cor-
ticosteroids such as dexamethasone suppress
HGF mRNA expression, and HGF produc-
tion and secretion (Matsumoto et al 1992,
Matsunaga et al 1994, Gohda et al 1994,
Takai et al. 1997). Moreover, a tendency
toward lower HGF was detectable in infants
receiving antenatal betamethasone. In ex-
tremely low birth-weight infants, postna-
tal dexamethasone does not reduce the risk
for development of BPD (Stark et al 2001).
Glucocorticoid treatment improves postna-
tal lung function and reduces mortality from




manent lung damage due to alveolar hypo-
plasia (Wíllet et al 2000). Glucocorticoids
have been shown to inhibit septation and
diminish the extent of the increase in al-
veolar surface area, resulting in emphyse-
matous-looking lungs (Massaro et al 1985,
Blanco et al 1989, Okajima et al 2001). It
may be that the beneficial effect of dexam-
ethasone is related to its effect on acute res-
piratory insufficiency; extremely low birth-
weight infants may however, have mild
RDS or no RDS at all, yet still develop BPD.
Postnatal dexamethasone may therefore
show no beneficial pulmonary effects in ex-
tremely immature infants; conversely, it
may worsen arrest of alveolar development.
Since HGF has been shown to participate
in epithelial repair after lung injury, we
suggest that inhibition of HGF may be re-
lated to the adverse influences of dexam-
ethasone on pulmonary development and on
repair of acute injury in the preterm lung.
5. VEGF in PPHN
In contrast to findings in term infants with-
out lung injury, we observed in PPHN in-
fants positive staining for VEGF and for Flt-
1 in type-II pneumocytes in alveolar epi-
thelium. Moreover, we found a tendency
toward higher concentrations of pulmonary
VEGF protein in PPHN infants than in
term infants without lung disease. In rats
recovering from lung injury, pulmonary
VEGF protein level increases and alveolar
type-II cells exclusively express VEGF
(Maniscalco et al 1995). The higher VEGF
in TAF in PPHN infants and the additional
expression of VEGF in alveolar epithelium
may represent an enhanced production of
VEGF due to impaired endothelial function
in PPHN. However, circulatory VEGF was
lower in our PPHN infants than in our term
infants without lung disease. Since VEGF
is a paracrine factor, it has been suggested
that VEGF leaks from different tissues into
the circulation (Shifren et al 1994). Lower
circulatory VEGF in PPHN infants may
therefore reflect an overall disturbance in
vascular development. Another explanation
is that the pulmonary bed may be an im-
portant source of circulating VEGF. In se-
vere PPHN, there is a right-to left-shunt
through the foramen ovale and also via the
ductus arteriorus if it remains open. Conse-
quently, pulmonary blood flow is dimin-
ished, which may contribute to low plasma
concentrations in these infants.
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Our findings of persistent pulmonary ex-
pression of VEGF and Flt-1 during the peri-
natal period, higher VEGF in TAF in
preterm than in term infants, and a postna-
tal increase in VEGF in TAF in preterm
infants all suggest a physiological role for
VEGF in the developing lung. Those
preterm infants who suffered more severe
RDS and those who subsequently developed
BPD had lower VEGF in TAF. These data
indicate a role for VEGF in the preterm lung
in protection or in recovery from acute lung
injury. Lower VEGF in these infants may
be related to the arrest of development seen
in infants developing BPD.
The significant amount of HGF in TAF
supports the notion of a role for HGF in
human lung development. Lower HGF in
human preterm infants with more severe
RDS and in those subsequently developing
BPD suggests a protective or regenerative
role for HGF in their lung injury. Reduced
levels of HGF but not of VEGF in their tra-
cheal aspirates during the early postnatal
period were evident in infants receiving
early postnatal dexamethasone therapy. The
suppressive effects of glucocorticoids on
lung development may in part be mediated




VEGF. Development of new BPD has been
suggested to be caused by arrest of normal
lung development: inhibition of capillary
growth and impairment of septation and
alveolarization (Jobe 1999, Abman 2001).
VEGF plays a pivotal role in vascular de-
velopment. A targeted deletion of VEGF,
of its hypoxia-inducible promoter HIF-2-
a, or of VEGF receptors; or inhibition of
VEGF all result in severe developmental
abnormalities and embryonic lethality
(Fong et al 1995, Shalaby et al 1995,
Carmeliet et al 1996, Ferrara et al 1996,
Bautch et al 2000, Compernolle et al 2002).
Inhibition of the VEGF receptor Flk-1 re-
sults in impaired alveolarization, alveolar
septal cell apoptosis, and emphysematous
lungs (Kasahara et al  2000, Compernolle
et al 2002). The insufficient surfactant pro-
duction and fatal RDS in HIF-2-a knock-
out mice can be reversed by intrauterine or
postnatal intratracheal instillation of VEGF
(Compernolle et al 2002). Because VEGF
is also a factor able to induce vascular per-
meability (Dvorak et al 1995), administra-
tion of VEGF can induce permeability-
caused pulmonary edema. In mice, however,
intratracheally administered VEGF does not
stimulate vascular leakage or bronchial
edema. Moreover, such VEGF remains re-
stricted to the alveolar compartment and
does not leak in significant amounts into
the circulation (Compernolle et al 2002).
These data indicate that VEGF administra-
tion has protective and reparative roles in
lung injury in neonatal mice. It may there-
fore be the case that in extremely preterm
human infants at risk for development of
BPD, intratracheal treatment with VEGF
will improve lung function and prevent
development of BPD.
HGF. Alveolar type-II cell proliferation
occurs in response to lung injury and is
thought to play a critical role in alveolar
epithelial repair (Daly et al 1998, Piedboeuf
et al 1996). HGF treatment in experimen-
tal animal lung injury stimulates DNA syn-
thesis of airway and alveolar epithelial cells,
induces time- and dose-dependent alveolar
type-II cell proliferation, and acts as a
pulmotrophic factor preventing the progres-
sion of injury (Panos et al 1996, Ohmichi
et al 1996, Yaekashiwa et al 1997).  On the
other hand, in the adult ARDS patient, a
high level of HGF is associated with poor
prognosis (Stern et al 2000), Moreover, in
adult rats with oxygen-induced lung injury,
HGF administration inhibits surfactant
metabolism in type-II cells in vitro
(Vivekananda et al 2000). Before one can
speculate as to the potential therapeutic use
of HGF in human preterm infants, in vivo
animal studies are needed to reveal whether
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